Purple Biotech (PPBT) 20-F 5 Mar 24 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2023 shares
Document Information Line Items
Entity Registrant Name	Purple Biotech Ltd.
Trading Symbol	PPBT
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	252,379,218
Amendment Flag	false
Entity Central Index Key	0001614744
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-37643
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	4 Oppenheimer Street
Entity Address, Address Line Two	Science Park
Entity Address, City or Town	Rehovot
Entity Address, Postal Zip Code	7670104
Entity Address, Country	IL
Title of 12(b) Security	American Depositary Shares, each representing 10 Ordinary Shares (1)
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm ID	1057
Auditor Name	KPMG International
Auditor Location	Tel-Aviv
Business Contact
Document Information Line Items
Entity Address, Address Line One	4 Oppenheimer Street
Entity Address, Address Line Two	Science Park
Entity Address, City or Town	Rehovot
Entity Address, Postal Zip Code	7670104
Entity Address, Country	IL
Contact Personnel Name	Lior Fhima
City Area Code	+972
Local Phone Number	3-933-3121
Contact Personnel Fax Number	+972-3-5097196

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 14,489	$ 15,030
Short term deposits	850	16,652
Other investments	73	431
Other current assets	376	1,143
Total current assets	15,788	33,256
Non-current assets
Right to use assets	316	467
Fixed assets, net	154	215
Intangible assets	28,044	20,684
Total non - current assets	28,514	21,366
Total assets	44,302	54,622
Liabilities
Current maturity of lease liabilities	188	194
Trade payable	3,532	2,132
Other payables	3,463	4,732
Total current liabilities	7,183	7,058
Non-current liabilities
Lease liability	163	321
Post-employment benefit liabilities	141	145
Warrants	2,518
Total non - current liabilities	2,822	466
Equity
Share capital, no par value
Share premium	133,184	126,407
Receipts on account of warrants	28,467	28,017
Capital reserve for share-based payments	10,088	10,164
Capital reserve from transactions with related parties	761	761
Capital reserve from hedging	19	(6)
Capital reserve from transactions with non- controlling interest	(859)	(859)
Accumulated loss	(137,453)	(117,573)
Equity attributable to owners of the Company	34,207	46,911
Non-controlling interests	90	187
Total equity	34,297	47,098
Total liabilities and equity	$ 44,302	$ 54,622

Consolidated Statements of Oper

Consolidated Statements of Operations and Other Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [Abstract]
Research and development expenses	$ 17,034	$ 16,320	$ 11,827
Sales, general and administrative expenses	5,237	6,283	6,107
Operating Loss	22,271	22,603	17,934
Change in fair value of warrants	(3,497)
Finance expenses	2,195	67	212
Finance income	(992)	(910)	(320)
Finance income, net	(2,294)	(843)	(108)
Loss for the year from continuing operations	19,977	21,760	17,826
Loss from discontinued operation			642
Loss for the year	19,977	21,760	18,468
Items that will be transferred to profit or loss:
Loss (profit) from cash flow hedges	(25)	6
Total comprehensive loss for the year	19,952	21,766	18,468
Loss attributable to:
Owners of the Company	19,880	21,668	18,384
Non-controlling interests	97	92	84
Loss for the year	19,977	21,760	18,468
Total comprehensive loss attributable to:
Owners of the Company	19,855	21,674	18,384
Non-controlling interests	97	92	84
Total comprehensive loss for the year	$ 19,952	$ 21,766	$ 18,468
Continuing operations
Basic loss per ADS - USD (in Dollars per share)	$ 0.9	$ 1.2	$ 1.01
Number of ADSs used in calculating basic loss per ADS (in Dollars per share)	22,133,294	18,081,087	17,568,036
Discontinued operation
Basic loss per ADS – USD (in Dollars per share)			$ 0.04
Number of ADSs used in calculation (in Shares)			17,568,036

Consolidated Statements of Op_2

Consolidated Statements of Operations and Other Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Profit or loss [Abstract]
Diluted loss per ADS - USD	$ 0.9	$ 1.20	$ 1.01
Number of ADSs used in calculating diluted loss per ADS	22,133,294	18,081,087	17,568,036
Diluted loss (profit) per ADS – USD			$ 0.04

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Share Capital	Share premium	Receipts on account of warrants	Capital reserve for share- based payments	Capital reserve from hedging	Capital reserve from transactions with related parties	Capital Reserve From Transactions With Non-Controlling Interest [Member]	Accumulated loss	Parent	Non- controlling interests	Total
Balance at Dec. 31, 2020		$ 118,909	$ 29,984	$ 8,115		$ 761	$ (859)	$ (77,521)	$ 79,389	$ 363	$ 79,752
Transactions with owners of the Company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		540							540		540
Exercise of warrants		3,167	(1,967)						1,200		1,200
Share-based payments		1,335		747					2,082		2,082
Total transactions with owners of the Company		5,042	(1,967)	747					3,822		3,822
Loss for the year								(18,384)	(18,384)	(84)	(18,468)
Balance at Dec. 31, 2021		123,951	28,017	8,862		761	(859)	(95,905)	64,827	279	65,106
Transactions with owners of the Company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		1,346							1,346		1,346
Share-based payments		1,110		1,302					2,412		2,412
Total transactions with owners of the Company		2,456		1,302					3,758		3,758
Loss for the year								(21,668)	(21,668)	(92)	(21,760)
Other comprehensive profit and loss for the period					(6)				(6)		(6)
Balance at Dec. 31, 2022		126,407	28,017	10,164	(6)	761	(859)	(117,573)	46,911	187	47,098
Transactions with owners of the Company:
Issuance of American Depository Shares (ADSs) on the NASDAQ, net of issuance costs		1,045	450						1,495		1,495
ADS issued in connection with the purchase of a subsidiary (see Note 5C)		3,781							3,781		3,781
Share-based payments		1,951		(76)					1,875		1,875
Total transactions with owners of the Company		6,777	450	(76)					7,151		7,151
Loss for the year								(19,880)	(19,880)	(97)	(19,977)
Other comprehensive profit and loss for the period					25				25		25
Balance at Dec. 31, 2023		$ 133,184	$ 28,467	$ 10,088	$ 19	$ 761	$ (859)	$ (137,453)	$ 34,207	$ 90	$ 34,297

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities from continuing operation:
Loss for the year from continuing operation	$ (19,977)	$ (21,760)	$ (17,826)
Adjustments:
Depreciation	197	201	231
Finance income, net	(2,294)	(843)	(108)
Share-based payments	1,875	2,412	2,082
Total adjustments	(20,199)	(19,990)	(15,621)
Changes in assets and liabilities:
Changes in other current assets	178	313	(316)
Changes in trade payable	1,334	799	399
Changes in other payables	(1,076)	2,132	634
Changes in post-employment benefit liabilities	(162)	11	27
Changes in assets and liabilities, total	274	3,255	744
Net cash used in operating activities from continuing operation	(19,925)	(16,735)	(14,877)
Cash flows from investing activities from continuing operation:
Acquisition of subsidiary, net of cash acquired (see Note 5C)	(3,549)
Proceed from other investments	875
Acquisition of intangible asset		(202)
Decrease in short term deposits	15,803	19,658	10,248
Decrease in long term deposits		160	2,914
Interest received	755	324	359
Acquisition of fixed assets	(3)	(26)	(115)
Net cash provided by investing activities from continuing operation	13,881	19,914	13,406
Cash flows from financing activities from continuing operation:
Proceeds from issuance of ADSs	1,563	1,498	564
ADS issuance expenses paid	(229)	(152)	(24)
Proceeds from issuance of ADSs, warrants and prefunded warrants	5,000
Warrants issuance expenses paid	(661)
Proceeds from exercise of warrant			1,200
Repayment of lease liability	(168)	(165)	(153)
Interest paid	(56)	(67)	(75)
Net cash provided by financing activities from continuing operation	5,449	1,114	1,512
Cash flows in respect of discontinued operation as follows:
Net cash from operating activities			(374)
Net cash used in discontinued operation			(374)
Net increase (decrease) in cash and cash equivalents	(595)	4,293	(333)
Cash and cash equivalents at the beginning of the year	15,030	10,890	11,247
Effect of translation adjustments on cash and cash equivalents	54	(153)	(24)
Cash and cash equivalents at end of the year	$ 14,489	$ 15,030	$ 10,890

General

General	12 Months Ended
	Dec. 31, 2023
General [Abstract]
General	Note 1 - General Reporting entity A. Purple Biotech Ltd. (hereinafter: the “ Company Purple The Company was incorporated in Israel as a private company in August 1968, and has been listed for trading on the Tel Aviv Stock Exchange since September 1978. In October 2012, the Company disposed of all of its previous operations, and in July 2013, the Company acquired shares of Kitov Pharma Ltd. from its shareholders, in exchange for the Company’s shares. In December 2020 the Company changed its name from Kitov Pharma Ltd. to Purple Biotech Ltd.. B. The Company’s securities (American Depository Shares (“ADS”)) were listed for trading on the NASDAQ in November 2015 (including a Series A warrant that expired in November 2020). Each ADS represents 10 ordinary shares with no par value following a reverse split in effect from August 23, 2020 (see Note 10A). Each 10 warrants enable the purchase of 1 ADS. The Company’s address is 4 Oppenheimer St., Science Park Rehovot 7670104 Israel. C. In January 2017, the Company acquired the majority of shares of TyrNovo Ltd. (hereinafter: “TyrNovo”). During 2018, the Company acquired additional shares of TyrNovo from various minority shareholders, see also Note 5A. In January 2020, the Company acquired 100% of FameWave Ltd. (hereinafter “FameWave”), see also Note 5B. In October 28, 2021, the Company established a fully owned subsidiary Purple Biotech GmbH (hereinafter “ Purple GmbH In February 2023, the Company acquired 100% of Immunorizon Ltd. (hereinafter “Immunorizon”), see also Note 5C. The Company together with TyrNovo, FameWave, Immunorizon and Purple GmbH are referred to, in these consolidated financial statements, as “ the Group D. Since incorporation through December 31, 2023, the Group has incurred losses and negative cash flows from operations mainly attributed to its development efforts and has an accumulated loss of USD 137.4 million. The Group has financed its operations mainly through private and public financing rounds. Through December 31, 2023, the Company raised (excluding exercise of warrants) a total of USD 101.5 million net of issuance expenses, see also Note 10. Management anticipates that its existing capital resources will be adequate to satisfy liquidity requirements for at least the next 12 months. Subsequently, management’s plans include pursuing alternative financing arrangements or reducing expenditures as necessary to meet the Company’s future cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. E. In October 2023, Hamas terrorists (hereinafter: Hamas) infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the clash between Israel and Hezbollah in Lebanon, may escalate in the future into a greater regional conflict. Any hostilities involving Israel, or the interruption or curtailment of trade within Israel or between Israel and its trading partners could adversely affect the Company’s operations and results of operations and could make it more difficult for the Company to raise capital. While five study sites out of 27 total study sites in the ongoing studies for CM24 and NT219 are located in Israel, the Company has not yet experienced any material interruptions or delays with respect to such studies, and the Company believes the study sites in Israel have sufficient supply of the therapeutic candidate to continue the studies, as applicable. Both CM24 and NT219 are manufactured by service providers outside of Israel. Most of the research and development work is being conducted by third-party entities outside of Israel. However, a prolonged conflict with Hamas can cause disruptions or delays to the study sites located in Israel, as the result of shortage of staff at study site, resulting in an adverse effect on the Company’s business, financial condition and results of operation. Additionally, all of Company’s employees are located and reside in Israel. Shelter-in-place and work-from-home measures, government-imposed restrictions on movement and travel and other precautions that may be taken to address the ongoing conflict may temporarily disrupt the employees’ ability to effectively perform the daily tasks. It is currently not possible to predict the duration or severity of the ongoing conflict or its effects on Company’s business, operations and financial conditions. The ongoing conflict is rapidly evolving and developing, and could disrupt Company’s business and operations, interrupt the sources and availability of supply and hamper the ability to raise additional funds or sell Company’s securities, among others.

Basis of Preparation of the Con

Basis of Preparation of the Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2023
Basis of Preparation of the Consolidated Financial Statements [Abstract]
Basis of Preparation of the Consolidated Financial Statements	Note 2 - Basis of Preparation of the Consolidated Financial Statements A. Statement of compliance with International Financial Reporting Standards The Group has prepared the consolidated financial statements in accordance with IFRS Accounting Standard (hereinafter: “IFRS”), as issued by the International Accounting Standard Board (“IASB”). These consolidated financial statements were approved by the board of directors on March 4, 2024. B. Functional and presentation currency These consolidated financial statements are presented in US dollars (USD), which is the Group’s functional currency, rounded to the nearest one thousand, unless otherwise noted. The USD is the currency that represents the principal economic environment in which the Group operates. C. Basis of measurement The consolidated financial statements have been prepared on the historical cost basis except for the following assets and liabilities: ● Financial instruments and derivatives measured at fair value through profit or loss; ● Provisions; ● Liabilities for employee benefits For further information regarding the measurement of these assets and liabilities see Note 3 regarding material accounting policies. D. Use of estimates and judgment The preparation of consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Management prepares the estimates on the basis of past experience, various facts, external circumstances, and reasonable assumptions according to the pertinent circumstances of each estimate. The preparation of accounting estimates used in the preparation of the Group’s consolidated financial statements requires management of the Group to make assumptions regarding circumstances and events that involve considerable uncertainty. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in the following notes: Estimate Principal assumptions Possible effects Reference Assessment of probability of contingent liabilities Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees Reversal or creation of a provision for a claim For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities Recoverability of intangible assets The discounted cash flows method includes assumptions such as future expenses, future revenues, success rates (in respect of transition between phases of the R&D of the clinical trials until reaching regulatory approval and marketing) and discount rate. Impairment of the in-process research and development in profit or loss See Note 5 regarding Intangible assets Determination of fair value Preparation of the financial statements requires the Group to determine the fair value of certain assets and liabilities. The Group’s management regularly reviews significant unobservable inputs and valuation adjustments, including obtaining valuations prepared by third parties and assessing the evidence to support the conclusion that these valuations meet the requirements of IFRS, including the level in the fair value hierarchy in which the valuations should be classified. When determining the fair value of an asset or liability, the Group uses market data as much as possible. There are three levels of fair value measurements in the fair value hierarchy that are based on the data used in the measurement, as follows: - Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities. - Level 2: inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. - Level 3: inputs that are not based on observable market data (unobservable inputs). Further information about the assumptions made in measuring fair value of share-based payments, intangible assets and financial instruments are included in Note 11, Note 5 and Note 19, respectively. E. Exchange rates and linkage bases Balances in foreign currency (mainly the New Israeli Shekel, or NIS) or linked thereto are included in the consolidated financial statements at the representative exchange rates, as published by the Bank of Israel, which were prevailing as of the statement of financial position date. Data on exchange rates are as follows: Representative exchange rate (NIS/USD 1) Date of consolidated financial statements: December 31, 2023 3.627 December 31, 2022 3.519 December 31, 2021 3.110 % Changes in exchange rates for the year ended: December 31, 2023 3 December 31, 2022 13 December 31, 2021 (3 ) F. Initial application of amendment to standard Amendment to IAS 1, Presentation of Financial Statements: "Disclosure of Accounting Policies." According to the amendment, the Company must provide disclosure of their material accounting policies rather than their significant accounting policies. Pursuant to the amendment, accounting policy information is material if, when considered with other information disclosed in the financial statements, it can be reasonably be expected to influence decisions that the users of the financial statements make on the basis of those financial statements. The amendment also clarifies that immaterial accounting policy information need not be disclosed. The amendment is initially applied in the annual financial statements for 2023. As a result of applying the Amendment, the extent of the accounting policy disclosure provided in the financial statements for 2023 was reduced and adjusted according to the Company’s specific circumstances.

Material Accounting Policies

Material Accounting Policies	12 Months Ended
	Dec. 31, 2023
Material Accounting Policies [Abstract]
Material Accounting Policies	Note 3 - Material Accounting Policies The accounting policies set out below have been consistently applied for all periods presented in these consolidated financial statements: A. Basis of consolidation 1. Acquisition of Subsidiaries Upon acquisition of subsidiaries, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts for the acquisition as a purchase of assets. The Company uses the optional concentration test to determine the accounting treatment of such acquisitions. In applying the concentration test, an entity determines whether substantially all the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If so, the asset is not considered a business. As of December 31, 2023, the acquisitions made by the Company were determined to be an acquisition of assets, see Note 5. Contingent considerations transferred for acquisition of subsidiaries are recorded when the terms and conditions for payment of the consideration are met. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the event of liquidation (for example: ordinary shares), are measured at the date of the business combination at fair value. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. B. Foreign currency transactions Transactions in foreign currencies are translated to USD which is the functional currency of Group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. C. Financial instruments 1. Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. Subsequent measurement and gains and losses Financial assets at fair value through profit or loss These assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss. 2. Non-derivative financial liabilities Non-derivative financial liabilities include: finance lease liabilities, accounts payables and other payables. Initial recognition of financial liabilities Financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent measurement of financial liabilities Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. 3. Derivative financial instruments As part of the October 2023 capital raising agreement, the Company issued new warrants and amended previous warrants that were classified as derivative financial instruments. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation and classified as level 3. 4. Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity. Incremental costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected to take place. 5. Issuance of parcel of securities The consideration received from the issuance of parcel of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is allocated to equity. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. As part of the October 2023 capital raising, the Company issued pre-funded warrants and amended terms for previous warrants. The Company classified the pre-funded warrants as an equity instrument due to their negligible exercise price. The amended terms for previously issued warrants increased the fair value of those warrants. The amended terms were part of the capital raising and therefore the Company accounted for the increase in value as issuance cost. D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involves research for new or substantially improved drug candidates and processes, the manufacturing of such candidates and the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo ,Famewave, Immunorizion, and asset purchased by Purple GmbH (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment may be needed. E. Impairment Timing of impairment testing The carrying amounts of the Group’s non-financial assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains intangible assets that have indefinite useful lives. Measurement of recoverable amount The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit, for which the estimated future cash flows from the asset or cash-generating unit were not adjusted. Recognition of impairment loss An impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss. F. Loss per share The Group presents basic and diluted loss per share data for its ordinary share capital (including pre-funded warrants). Basic loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the year. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of 10 shares per 1 ADS. G. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. H. Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest. I. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. A provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation can be estimated reliably. J. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of financial assets at fair value through profit or loss and income from short- term and long-term deposits, foreign currency gains, and the reclassification of net gains and losses previously recognized in other comprehensive income on cash flow hedges of foreign currency. Finance expenses include loss from exchange rate differences and interest fee. Interest income or expense is recognized, using the effective interest method. In the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented as part of cash flows from financing activities. K. Income tax expense Income tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they relate to a business combination, or are recognized directly in equity or in other comprehensive income. Deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. The Company has not recognized deferred tax assets as no future taxable profits are expected in the foreseeable future. L. Leases Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group’s leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Depreciation of right-to-use asset After lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over contractual lease period as follows: office lease from September 15 2020 for 5 years and 3.5 months. M. Discontinued operations A discontinued operation is a component of the Group’s business that represents a separate major line of business that has been disposed of or is held for sale or distribution. Classification as a discontinued operation occurs upon disposal or when the operation meets the criteria to be classified as held for sale, if earlier. When an operation is classified as a discontinued operation, the comparative statement of operation is restated as if the operation had been discontinued from the start of the earliest comparative period.

Discontinued Operation

Discontinued Operation	12 Months Ended
	Dec. 31, 2023
Discontinued Operation [Abstract]
Discontinued operation	Note 4 - Discontinued operation In October 2021, the Company agreed, together with its then U.S distributor for Consensi (an FDA approved fixed-dose combination drug treatment intended for the treatment of osteoarthritis pain and for hypertension, hereinafter “Consensi”), Coeptis Pharmaceuticals Inc., to terminate the distribution agreement. Despite the Company’s efforts to identify an alternative distributor for Consensi in the United States., the Company concluded that commercialization of Consensi, both in the U.S market and elsewhere, is not likely to generate significant revenue and achieve profitability in the near term. In order to reduce the expenses involved in maintaining the product, it was concluded to discontinue Consensi activities and to allocate the funds to the Company’s core oncology activities. In parallel, the agreements with Kuhnil Pharmaceuticals Inc.’s for the territory of South Korea and Hebei Changshan Biochemical Pharmaceutical Co., Ltd. for the territory of China were terminated. Consensi represented a separate major line of business. Discontinuation also included inventory write off. Consequently, the Company reported Consensi as a discontinued operation and as of December 31, 2021 has one operating segment- oncology. 2021 USD thousands Results of discontinued operation Revenue - Expenses 642 Loss for the year 642 Loss for the year attributable to the owners of the Company: From continuing operations 17,826 From discontinued operation 642 Loss per share – Discontinued operation Basic & diluted loss per ADS – USD 0.04 Cash flows from discontinued operation Net cash used in operating activities (374 )

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
Intangible Assets	Note 5 - Intangible Assets As of December 31, 2023, and 2022: 2023 2022 USD thousands IPR&D related to TyrNovo (see 5A below) 6,172 6,172 IPR&D related to Famewave (see 5B below) 14,310 14,310 IPR&D related to Immunorizon (see 5C below) 7,360 - IPR&D related to Purple GmbH 202 202 Total intangible assets 28,044 20,684 A Acquisition of Tyrnovo During the years 2017 to 2019 the Company acquired shares in Tyrnovo, a company developing NT219. Since 2019 the Company owns 98.47% of Tyrnovo. B. Acquisition of Famewave On January 7, 2020 the Company completed the purchase of 100% of FameWave Ltd, a privately held biopharmaceutical Company developing CM24, (“FameWave”). The consideration was recorded based on the fair value of the assets purchased. C. Acquisition of Immunorizon In February 2023 the Company completed the acquisition of 100% of Immunorizon Ltd, a privately held biopharmaceutical Company developing potential multispecific T and NK cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment, (“Immunorizon”) from its shareholders in consideration of an aggregate upfront payment of $3.5 million in cash, an aggregate of $3.5 million in ADSs (or 2,215,190 ADSs representing ordinary shares at a price per ADS equal to the NASDAQ volume-weighted average price of the Company’s ADSs for the 60-day period preceding the execution date of the agreement) with three months lock up period including a price protection mechanism for 12 months (see Note 10D1). Additional future considerations include future payments when achieving certain long-term milestones set at an aggregate amount of $94 million, including royalties on net sales. The acquisition closed on February 15, 2023. The total acquisition amounted to $ 3.6 million. The acquisition was recorded based on the fair value of the consideration transferred and was accounted for as an asset purchase as it did not meet the definition of a business combination in accordance with IFRS 3. Identifiable assets acquired and liabilities assumed The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition: USD thousands Cash 44 Intangible asset (1) 7,360 Other receivables 1 Trade payables (28 ) Other payables (2 ) Total net identifiable assets 7,375 (1) Intangible asset - In process research and development The fair value of the intangible asset recognized at the acquisition date was determined according to the fair value of the issued equity (2,215,190 ADSs) which amounted to USD 3,781 thousand and the cash paid. According to the agreement, the equity issued included a price protection mechanism as well as a lock up period of three months. The fair value of equity issued was based on the assumptions below: a. Share price - 1.59 b. Expected volatility - 70.89% c. Annual risk-free rate – 4.5% d. Dividend yield- 0% e. DLOM – 10.8% D As of December 31, 2023, the recoverable amount of the in-process research and development assets (hereinafter – “intangible assets”) was based on their value in use and was determined by discounting the future cash flows to be generated from them by using the discounted cash flows method, on the annual year test. The recoverable amount of the intangible assets exceeds their carrying amount, thus no impairment loss was recognized. The discounted cash flows model considered the risks associated with the clinical/preclinical phase of the intangible assets and the probability of success for each development phase. Certain estimations were determined using industry data reports. The discount rate used for calculating intangible assets recoverable amount was 18.9%. The Company performed sensitivity analysis for estimations such as discount rate and royalty rate and concluded that the recoverable amount of the intangible assets exceeds their carrying amount.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents	Note 6 - Cash and Cash Equivalents As of December 31, 2023 2022 USD thousands Balance in USD 14,007 11,902 Balance in other currencies 482 3,128 Total cash and cash equivalents 14,489 15,030

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	Note 7 – Leases The Group has lease agreements with respect to offices. A. Information regarding material lease agreements The Company entered into an agreement for the lease of offices in Rehovot as from September 15, 2020 for a period of 5 years. Accordingly, the Company initially recognized in the statement of financial position a right-to-use asset in the amount of USD 817 thousand concurrently with the recognition of a lease liability in the same amount. This additional period is not included in the lease payments used-in the calculation of the liability as the Company does not expect it is reasonably certain it will exercise the option. The Company has an option to extend the lease agreements for an additional 5 years at the terms as those of the existing agreement with addition of 5% to the current terms and CPI linked. B. Right-to-use assets Carrying amounts of right-to-use assets and change during the period: Office lease USD thousands Balance as of January 1, 2023 467 Depreciation on right-to-use assets (151 ) Balance as of December 31, 2023 316 Balance as of January 1, 2022 619 Depreciation on right-to-use assets (152 ) Balance as of December 31, 2022 467 C. Lease liability Maturity analysis of the Company’s lease liabilities December 31, December 31, 2023 2022 USD thousands USD thousands Less than one year 188 204 One to two years 188 388 Total 376 592 Current maturities of lease liability 188 194 Long-term lease liability 163 321 D. Additional information on leases Amounts recognized in profit or loss 2023 2022 USD thousands USD thousands Interest expenses on lease liability 37 49

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2023
Other Current Assets [Abstract]
Other Current Assets	Note 8 - Other Current Assets As of December 31, 2023 2022 USD thousands Government authorities 171 146 Prepaid expenses and other receivables 205 997 Total other current assets 376 1,143

Other Payables

Other Payables	12 Months Ended
	Dec. 31, 2023
Other Payables [Abstract]
Other Payables	Note 9 - Other Payables As of December 31, 2023 2022 USD thousands Due to related parties - salary related 620 607 Accrued expenses 2,521 3,597 Government authorities 53 81 Salary related 269 437 Other payables - 10 3,463 4,732

Equity

Equity	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Equity	Note 10 - Equity A. The Company’s authorized share capital is 1,000,000,000 ordinary shares, with no par value, and 50,000,000 non-voting senior preferred shares, with no par value, divided into 5 classes of 10,000,000 preferred shares in each class. On August 21, 2020 the ratio between ADSs and shares was changed from 1:1 to 1:10 (each 1 ADS equal 10 shares). B. The Company’s share capital As of December 31, As of December 31, Number of shares in thousands Authorized Issued and Authorized Issued and Shares, no par value 1,000,000 252,379 1,000,000 184,815 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 - C. Changes in share capital during the year For the year ended December 31 2023 2022 2021 Number of ADSs in thousands Issued as at January 1 18,482 17,800 17,211 Issuance of ADSs (See D below and 5C) 6,388 544 126 Vesting of RSUs 368 138 163 Exercise of warrants - - 300 Issued as at December 31 25,238 18,482 17,800 D. Financing rounds 1. On October 19, 2023, in a registered direct offering on the NASDAQ, the Company raised USD 5 million gross (approximately USD 4.3 million net of placement agent fees). In this registered direct offering, the Company issued an aggregate of 2,430,000 ADSs at a purchase price of USD 1.15 per ADS and pre-funded warrants to purchase up to 1,917,827 ADS. The Company also issued unregistered warrants to purchase up to an aggregate of 4,347,827 ADSs (hereinafter the “October 2023 warrants”) which are immediately exercisable, that were recorded as a liability at their fair value at a value of USD 5,348 thousand. The October 2023 warrants have a term of five and a half years and have an exercise price of USD 1.25 per ADS. During 2023, no warrants were exercised. In connection with the offering and effective upon October 19, 2023, the Company amended certain existing warrants to purchase up to an aggregate of 631,556 ADSs that were previously issued in June 2020 and June 2018 at exercise prices of $9.00 and $28.00 per ADS, respectively, such that the amended warrants have a reduced exercise price of $1.25 per ADS and an extended term of five and a half years from the closing of the offering. The company recorded USD 761 thousand in issuance expenses in relation to the amendment. During 2023, no warrants were exercised. In addition, the Company issued to the placement agent (or its designees) unregistered compensation warrants to purchase up to 304,348 ADSs at a value of USD 357 thousand at an exercise price of USD 1.4375 per ADS. The unregistered placement agent warrants are immediately exercisable and have a term of five years from the date of October 19, 2023. In connection with the October 2023 Offering, the Company issued 699,495 ADSs pursuant to an anti-dilution mechanism of that certain Lock-Up and Registration Rights Agreements entered into with former Immunorizon shareholders in connection with the acquisition of Immunorizon in February 2023 (refer to Note 5C). 2. On June 9, 2021, the Company entered into sales agreement with Jefferies LLC, for the sale of ADSs. In accordance with the terms of the sales agreement, the Company may offer and sell ADSs from time to time through Jefferies, acting as the Company’s agent. The Company originally filed a prospectus for a $50.0 million “at the market” equity offering program (“ATM Program”), but the aggregate offering price was subsequently reduced to $21.0 million on March 23, 2022, and to $3.0 million on October 17, 2023. During 2023, 2022 and 2021 the Company sold, under the ATM Program, 1,044,040, 543,400 and 126,160 ADSs at an average price of $1.63, $2.65 and $4.46 per ADS and raised USD 1.56 million, USD 1.49 million and USD 0.56 million gross (approximately USD 1.5 million, USD 1.44 million and USD 0.54 million net of placement agent fees), respectively. E. Other equity transactions 1. During 2023, the Company issued 3,680 thousand ordinary shares on account of vested RSUs granted in 2021, 2022 and 2023 to officers, board members and employees. 2. During 2022, the Company issued 1,380 thousand ordinary shares on account of vested RSUs granted in 2020 and 2021 to officers, board members and employees. 3. During 2021, the Company issued 1,634 thousand ordinary shares on account of vested RSUs granted in 2020 to officers, board members and employees. 4. In February 2023 the Company acquired Immunoraizon – see note 5C. F. Non-controlling interests The following table summarizes the information relating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations: December 31, December 31, TyrNovo Ltd. in USD thousands Non-current assets 6 10 Current assets 247 428 Current liabilities (23,419 ) (17,240 ) Net assets (23,166 ) (16,802 ) Net assets attributable to non-controlling interests (355 ) (258 ) Loss for the year 6,365 5,983 Loss allocated to non-controlling interests 97 92

Share-Based Payment Arrangement

Share-Based Payment Arrangements	12 Months Ended
	Dec. 31, 2023
Share-based Payment Arrangements [Abstract]
Share-based Payment Arrangements	Note 11 - Share-based Payment Arrangements A. On March 2, 2023, the board of directors of the Company granted 45 thousand options (to purchase the equivalent of 4,500 ADSs) and 45 thousand RSUs (equivalent to 4,500 ADSs) to an employee. The options have an exercise price of USD 0.198 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 16 thousand. On April 24, 2023, the board of directors of the Company granted 2,732 thousand options (to purchase the equivalent of 273 thousand ADSs) and 2,732 thousand RSUs (equivalent to 273 thousand ADSs) to the Board members, subject to the approval of the shareholders, and to employees. The options have an exercise price of USD 0.190 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 729 thousand. The board members grant was approved by the shareholders on June 15, 2023. On October 31, 2022, the board of directors of the Company granted 750 thousand options and 750 thousand RSUs to an employee. The options have an exercise price of USD 0.208 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 267 thousand. On July 11, 2022, the board of directors of the Company granted 3,750 thousand options and 150 thousand RSUs to the new CEO, subject to approval in the annual general meeting. The options have an exercise price of USD 0.245 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 591 thousand. This grant was approved by the shareholders on August 25, 2022. On May 23, 2022, the board of directors of the Company granted 6,635 thousand options and 5,885 thousand RSUs to officers and employees. The options have an exercise price of USD 0.304 per one ordinary share, and for certain employee and consultant USD 0.276 per one ordinary share eligible as from June 23, 2022. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 3,237 thousand. On November 7, 2021, the board of directors of the Company granted 112 thousand options and 112 thousand RSUs to new director, subject to his election in the annual general meeting. The options have an exercise price of USD 0.470 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 73 thousand. On August 31, 2021, the board of directors of the Company granted 420 thousand options and 420 thousand RSUs to new officer and employee. The options have an exercise price of USD 0.492 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 268 thousand On June 7, 2021, the board of directors of the Company granted 638 thousand options and 488 thousand RSUs to directors, officers and employees. The options have an exercise price of USD 0.470 per one ordinary share. The options and RSUs will vest over 3 years from the date of grant. The options are exercisable for 5 years from grant date. The fair value of these options and RSUs as of the grant date was measured at USD 406 thousand. This grant to directors was approved by the shareholders in December 29, 2021 and the vesting period begun accordingly. B. The number and weighted average exercise prices (in USD) of share options are as follows: Weighted average exercise price Number of options 2023 2022 2021 2023 2022 2021 Outstanding on January 1 0.52 0.97 1.02 18,468,235 7,751,303 6,994,377 Expired and forfeited during the year 0.54 0.82 1.52 (2,026,452 ) (418,068 ) (413,074 ) Granted during the year 0.19 0.28 0.47 2,777,000 11,135,000 1,170,000 Outstanding on December 31 0.46 0.52 0.97 19,218,782 18,468,235 7,751,303 Exercisable on December 31 0.62 0.97 1.48 10,923,032 6,144,318 4,451,430 The exercise price is denominated in NIS and are re-measured using historic exchange rates. Options are exercisable to shares, each ADS represent 10 shares. The options outstanding at December 31, 2023 had an exercise price of USD 0.190- USD 6 (2022 - USD 0.208- USD 6, 2021 -USD 0.346- USD 6), and weighted average contractual life of 3.10 years (2022 – 3.87 years, 2021 – 3.9 years). C. The number of RSUs are as follows: Number of RSUs 2023 2022 Outstanding at January 1 7,857,917 2,610,000 Granted during the year 2,777,000 6,785,000 Forfeited during the year (1,187,292 ) (157,083 ) Vested during the year (3,676,875 ) (1,380,000 ) Outstanding at December 31 5,770,750 7,857,917 Each RSU is convertible to one share, each ADS represent 10 shares. D. The fair value of the Company’s share options granted to employees, directors and consultants, where fair value of service was not measurable, was measured using the binominal model, using the fair value of the traded warrants with similar terms, making certain adjustments to reflect the specific terms of the options based on the expected duration. E The following assumptions were used : 2023 2022 Share Price - USD 0.160-0.226 0.213-0.316 Exercise price - USD 0.19-0.2 0.208-0.304 Expected volatility (%) 93.54-96.04 91.64-96.26 Expected duration (years) 2-5 2-5 Dividend yield (%) - - Risk free rate interest rate (%) 3.56%-4.31% 2.90%-4.28% F. Expenses recognized in the consolidated financial statements: For the year ended 2023 2022 2021 USD thousands Research and development expenses 768 768 557 General and administrative expenses 1,107 1,644 1,525 Total share-based expense recognized 1,875 2,412 2,082

Transactions and Balances with

Transactions and Balances with Related Parties	12 Months Ended
	Dec. 31, 2023
Transactions and Balances with Related Parties [Abstract]
Transactions and Balances with Related Parties	Note 12 - Transactions and Balances with Related Parties In addition to their salaries or fees, the Group also provides share option programs to directors and officers and contributes to a post-employment defined contribution plan on behalf of employees, see Note 9 for the balances and Note 11 regarding share based payments. The CEO is entitled to termination benefits of up to 6 monthly salaries or fees, See Note 18. In addition, the Company pays the chairman of the board a monthly fee for his service as the chairman of our medical and clinical committee, and a monthly fee to one of the directors who has been engaged as an advisor in a 50% capacity. Expenses of key management personnel: The Company recorded expenses to executive officers: For the year ended December 31 2023 2022 2021 USD thousands Short - term employee benefits 2,066 2,623 2,402 Post-employment benefits 12 11 27 Share based payments 1,346 1,930 1,446 3,424 4,564 3,875 The Company recorded expenses to directors: For the year ended December 31 2023 2022 2021 USD thousands Short - term benefits 427 448 323 Share based payments 284 311 478 711 759 801

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2023
Commitments and Contingent Liabilities [Abstract]
Commitments and contingent liabilities	Note 13 - Commitments and contingent liabilities A. Commitments 1. TyrNovo, has obligations to the Israel Innovation Authority (hereinafter: “IIA”) with respect to grants it received from the IIA in connection with TyrNovo’s technology. The requirements and restrictions for such grants are found in the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984 and in the IIA’s rules and guidelines and the terms of these grants. In general, a recipient company is obligated to pay the IIA royalties from the revenues generated from the sale of products and related services developed as a result of, a research and development program funded , in whole or in part, by the IIA (currently a yearly rate of 3% to 6%), up to the aggregate amount of the total grants received by the IIA, plus annual interest. The recipient company is also obligated to manufacture its drug in Israel unless it receives the approval of the IIA in which case it will be required to pay the higher rate mentioned above. A recipient company is not required to repay the grants if it does not generate revenue. TyrNovo’s technologies were developed, in part, with funds from IIA grants, and accordingly is obligated to pay royalties on sales of any of its IIA funded products and related services. As of December 31, 2023, the maximum royalty amount that would be payable by TyrNovo, excluding interest, is approximately NIS 5.5 million (USD 1.52 million), and as of such date, TyrNovo had not paid any royalties to the IIA. The Group does not recognize a liability for royalties because there is no reasonable assurance, as of the reporting period, that the underlying sales will occur in the future. Therefore, the financial statements do not include a liability for these royalties. 2. TyrNovo has entered into a license agreement (the “License Agreement”) with Yissum Research Development company of the Hebrew University of Jerusalem Ltd. (hereafter “Yissum”) dated August 15, 2013, as amended. In accordance with the License Agreement, Yissum granted the Company an exclusive license to commercialize, exploit, develop, manufacture, market, import, export, distribute, offer to sell, or sell products, that are derived from Yissum’s licensed technology. In consideration for the grant of the license, the Company shall pay Yissum the following consideration during the term of the license: (i) Royalties at a rate of up to three percent (3%) of net sales. (ii) Sublicense fees at a rate of twelve percent (12%) of sublicense consideration. In addition, Yissum is entitled to receive an exit fee of 12% of the transaction proceeds in the event of certain pre - defined transactions set forth in the License Agreement. BIRAD Research & Development Company Ltd. (BIRAD) is entitled to receive a portion of Yissum’s royalties on net sales according to an amendment to the License Agreement signed between TyrNovo and Yissum. The consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is no minimum payments and thus obligation will be recognized when the related sales will occur. 3. cCAM Biotherapeutics Ltd. (cCam), a subsidiary of Merck Sharp and Dohme Corp. (MSD), has entered into a license agreement with Tel Hashomer – Medical Research Infrastructure and Services Ltd. (“THM”) and Ramot at Tel Aviv University Ltd. (“Ramot”) dated April 16, 2012, which was effective as of May 25, 2010, as subsequently amended (the “THM License Agreement”). In conjunction with the closing of the reversion agreement amongst (MSD), cCAM and FameWave, the parties executed an Assignment and Assumption Agreement by and between FameWave and cCAM, according to which cCAM assigned to FameWave all its rights, title and interest in, to and under the THM License Agreement. Pursuant to the THM License Agreement, THM and Ramot granted FameWave a worldwide, royalty-bearing, exclusive license to develop, manufacture, produce, market and sell any biopharmaceutical product and/or diagnostic product using patents and inventions owned by THM and Ramot in connection with uses of the glycoprotein CEACAM1. In consideration for the license grant, FameWave shall pay to THM the following during the term of the license: i) An annual license fee of $10,000 which is credited towards any royalties to be paid during such year. ii) Royalties of three and a half percent (3.5%) of net sales with respect to Biopharmaceutical Products, and royalties of six and a half percent (6.5%) of net sales with respect to Diagnostic Products. iii) Sublicense fees at a rate of twenty percent (20%) of sublicense consideration with respect to Biopharmaceutical Products, and sublicense fees at a rate of twelve percent (12%) of sublicense consideration with respect to Diagnostic Products. FameWave has undertaken to pay certain milestone payments upon the completion of certain pre-defined clinical and sales milestones. In addition, THM (on behalf of the licensors) are entitled to receive an exit fee of up to three and a half percent (3.5%) of all consideration received because of or in connection with an exit event (as defined in the THM License Agreement). Finally, THM also received an assignable warrant to purchase, upon the closing of any IPO of FameWave, ordinary shares of FameWave, at a price equal to a certain percentage of the forecast initial market value of FameWave for each share as determined, prior to the IPO, for the purpose of the IPO. In accordance with the THM License Agreement, THM is entitled to appoint an observer to FameWave’s board of directors who has all the rights of any other director of FameWave expect for the right to vote. To date, THM has not acted on this right. The consolidated financial statements do not include a liability for royalties or sublicense fees for this license agreement as there is no minimum payments and thus obligation will be recognized when the related sales will occur. B. Claims 1. In December 2015, a lawsuit and a motion to approve such lawsuit as a class action was filed in the Tel Aviv District Court (Economic Division) against the Company and its directors, by shareholders who were holders of the Company’s Tel Aviv Stock Exchange listed securities before the Company’s initial public offering in the United States (the “U.S. IPO”) that took place in November 2015, claiming damages for the purported class in the motion totaling NIS 16.4 million (USD 4.6 million) due to the U.S. IPO (the “Motion”). In addition to this amount, the petitioners in the motion are seeking remedies in order to redress discrimination against the purported class owing to the dilution caused by the public offering, including the possibility that the purported class should be awarded from the Company amounts reflecting the losses of the purported class from a possible price increase in our shares following the announcement of the Phase III clinical trial results. The Company delivered its response to the court. Preliminary hearings initiated by the court in September 2016 and continued during 2017. On October 24, 2017 the court issued a ruling to stay proceedings in this matter until January 15, 2018 due to the ongoing ISA Investigation (See Note 13B(3) below). At the request of the ISA, this stay was subsequently extended several times by the court. Following approval of an enforcement arrangement in connection with the ISA investigation, the stay was lifted. On April 27, 2022 the evidentiary hearing took place and thereafter, the parties furnished their summaries and response summaries. On May 21, 2023, the Tel Aviv District Court (Economic Division) dismissed the lawsuit and motion to approve the lawsuit as a class action lawsuit pursuant to the Class Action Lawsuits Law 5766-2006 (the “2015 Motion”), which was filed against us and our directors on December 3, 2015, and ordered the plaintiffs to pay the Company NIS 43,000 in legal expenses. 2. On November 8, 2016, a shareholder of the Company submitted a request to the court in connection with the Motion to be excluded from the purported class, claiming to have independent causes of action and damages of approximately NIS 1 million (USD 284 thousand) (the “Petition to Exclude”). The Company responded to the court. In May 2018, the shareholder filed an independent lawsuit against the Company in the Haifa Magistrates Court seeking damages of approximately NIS 1.1 million (USD 354 thousand) and for the purposes of the court fees, the amount claimed was reduced to 750,000 NIS (USD 213 thousand) (the “Separate Lawsuit”). In August 2018, the Haifa Magistrates Court transferred the Separate Lawsuit to the Tel Aviv Magistrates Court. A preliminary hearing on the Company’s motion to dismiss the Separate Lawsuit and/or stay the proceedings was held in May, 2019, at which the court dismissed the claim without prejudice. This shareholder subsequently filed a new separate claim against the Company. In January 2020, the Tel Aviv District Court – Economic Division accepted the Company’s position that the shareholder’s claims are identical to the asserted claims for damages in the Motion, and entered a stay of proceedings pending the outcome of the Motion. As result of the dismissal of the 2015 Motion on May 21, 2023 as described above, this separate, independent lawsuit files in the Haifa Magistrates Court in May 2018 by a shareholder seeking damages identical to the asserted claims for damages in the 2015 Motion, was also dismissed. 3. In February 2017 the Company announced that the Israeli Securities Authority (the “ISA”) has begun a formal investigation into, amongst other matters, the Company’s public disclosures around certain aspects of the studies related to its therapeutic candidate, Consensi. In February 2017, four lawsuits and motions to approve the lawsuits as a class action lawsuit (each, a “Motion”), were filed against the Company and certain of its office holders at the Tel Aviv District Court (Economic Division), with each Motion relating to the ISA Investigation (the “2017 Motions”). One of these motions was subsequently withdrawn. The petitioners in one of the motions petitioned the court to dismiss the other two of the 2017 Motions (“Petition for Dismissal”). On December 19, 2017 the court granted the Petition for Dismissal and dismissed the other remaining 2017 Motions. The remaining motion (the “Surviving Motion”) was filed against the Company, the Company’s executive directors and certain of its present and former directors, by certain shareholders who are requesting to act as representatives of all shareholders of record from December 10, 2015 until February 6, 2017. The plaintiffs allege, among other things, that the Company included misleading information in its public filings which caused the class for which the plaintiffs are seeking recognition an aggregate loss of approximately NIS 29 million (approximately USD 8.2 million). The court ordered a stay of proceedings due to the then-ongoing ISA Investigation. Following approval of an enforcement arrangement in connection with the ISA investigation, the stay was lifted. The claim is still pending court proceeding. In November 2022 an evidence hearing was conducted. On June 8, 2023 the plaintiff’s summaries were filed. The respondents must furnish their summaries no later than March 17, 2024. The Company rejects the claims in the Surviving Motion. The Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the Surviving Motion as to the probability of success or the scope of potential exposure, if any. Therefore, no provision for this matter was recorded in these financial statements. 4. On November 17, 2022, Fidelity Venture Capital Ltd., a private Israeli company (“Fidelity VC”) and Mr. Dror Atzmon, an Israeli resident and citizen believed to be the sole shareholder of Fidelity VC (Mr. Atzmon, together with Fidelity VC, the “Atzmon Plaintiffs”), filed a statement of claim in the Economic Division of the Tel Aviv District Court (the “Atzmon Claim”) against the Company and a number of other defendants, including our former chief executive officer. The Atzmon Plaintiffs are seeking damages for approximately NIS 9 million (approximately USD 2.5 million) in connection with various claims relating to alleged contractual breaches and torts arising from an alleged contractual undertaking for the Company to engage the Atzmon Plaintiffs to provide advisory services to the Company following the initial public offering in the United States and listing on NASDAQ in November 2015. The Company rejects all the claims presented in the Atzmon Claim. On August 3, 2023, the court ordered the parties to inform of their willingness to a mediation process. The parties agreed to a mediation process, a mediator has been appointed and a mediation meeting is due to be scheduled for March 2024. At this preliminary stage the Company is unable, with any degree of certainty, to make any evaluations or any assessments with respect to the probability of success or the scope of potential exposure, if any, of the Atzmon Claim.

Research and Development Expens

Research and Development Expenses	12 Months Ended
	Dec. 31, 2023
Research and Development Expenses [Abstract]
Research and Development Expenses	Note 14 - Research and Development Expenses For the year ended December 31 2023 2022 2021 USD thousands Salaries, wages and related expenses 2,323 2,382 1,721 Share-based payments (see also Note 11) 768 768 557 Service providers 13,943 13,170 9,549 17,034 16,320 11,827

Sales, General and Administrati

Sales, General and Administrative Expenses	12 Months Ended
	Dec. 31, 2023
Sales, General and Administrative Expenses [Abstract]
Sales, General and Administrative Expenses	Note 15 - Sales, General and Administrative Expenses For the year ended December 31 2023 2022 2021 USD thousands Salaries, wages and related expenses 1,769 1,845 1,762 Share-based payments (see also Note 11) 822 1,333 1,047 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 13B) - 135 12 Reimbursement of legal fees (116 ) (63 ) (66 ) Other professional fees 1,004 750 1,222 Board member remuneration and insurance 818 1,152 1,033 Board member share-based payments 284 311 478 Maintenance expenses 196 120 55 Travel and car expenses 130 144 133 Depreciation 199 201 231 Other 131 355 200 5,237 6,283 6,107

Finance Expense (Income), Net

Finance Expense (Income), Net	12 Months Ended
	Dec. 31, 2023
Finance Expense (Income), Net [Abstract]
Finance Expense (Income), net	Note 16 - Finance Expense (Income), net A. Revaluation of warrants The gain is related to the fair value adjustments of warrants. The 2023 warrants included a cashless exercise feature and customary conditions in case of occurrence of a fundamental transaction. The warrants will expire (unless exercised) within 5.5 years from issuance of those warrants. B. Finance expenses and income For the year ended December 31 2023 2022 2021 USD thousands Finance expenses Fees and interest expense 56 67 79 Loss from exchange rate differences, net 13 - 133 Issuance expenses (see note 10D) 2,126 - - 2,195 67 212 For the year ended December 31 2023 2022 2021 USD thousands Finance income Interest income from deposits (474 ) (532 ) (320 ) Income from exchange rate differences, net - (62 ) - Changes in fair value of finance instruments (517 ) (245 ) - Other (1 ) (71 ) - (992 ) (910 ) (320 )

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2023
Taxes on Income [Abstract]
Taxes on Income	Note 17 - Taxes on Income A. Corporate tax rate The tax rate applicable to the Group is 23%. B. Carry-forward losses The Company and its subsidiaries incurred losses through 2023, which are not expected to be utilized in the foreseeable future. Therefore, the Group did not record current taxes or deferred tax assets. In 2023, the main reconciling item from the statutory tax rate of the Company (23%, representing theoretical tax benefit of approximately USD 4.6 million) to the effective tax rate (0%) is mainly due to the fact that deferred taxes were not created in respect of current year tax losses and benefits. The carry-forward loss for tax purposes of the Company and its subsidiaries, and the unrecognized research and development expenses, amounts to USD 96 million as of December 31, 2023 (2022 – USD 82 million, 2021 – USD 59 million).

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2023
Employee Benefits [Abstract]
Employee benefits	Note 18 - Employee benefits A. Employee benefits include post-employment benefits and short-term benefits. Balances include: For the Year ended 2023 2022 USD thousands USD thousands Short-term benefits 549 463 Post-employment benefit liabilities 141 145 Post-employment benefit liabilities included in other payables - 158 B. Post-employment benefit plans – defined contribution plan The Company has a defined contribution plan in respect of the Company’s liability in respect of its employees who are subject to Section 14 of the Severance Pay Law – 1963. For the Year ended December 31 2023 2022 2021 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 401 390 291 C. Certain of the Company’s executives are entitled to annual and special bonuses under the terms of their employment and consulting agreements. These bonuses will become due upon the achievement of certain goals or agreements for the commercialization of the Company’s products. These consolidated financial statements include bonuses expenses in the amount of USD 446 thousand for the year ended December 31, 2023, USD 406 thousand for the year ended December 31, 2022, and USD 580 thousand for the year ended December 31, 2021. D. Certain of the Company’s executives are entitled to benefits upon termination of employment under the terms of their employment and consulting agreements, see Note 12 on related parties. These benefits are measured based on the time of service and their monthly pay and the expected term of their employment. These consolidated financial statements include a liability due to these grants of USD 141 thousand and USD 303 thousand, as of December 31, 2023 and 2022, respectively.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2023
Financial Instruments [Abstract]
Financial Instruments	Note 19 - Financial Instruments Framework for risk management The Board of Directors has overall responsibility for the establishment and oversight of the Group’s risk management framework. The Group’s risk management practice was formulated to identify and analyze the risks that the Group faces, to set appropriate limits for the risks and controls, and to monitor the risks and their compliance with the limits. The risk policy and risk management methods are reviewed regularly to reflect changes in market conditions and in the Group’s operations. The Group acts to develop an effective control environment in which all employees understand their roles and commitment. The Group Audit Committee oversees how management monitors compliance with the Group’s risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Group. The Group Audit Committee is assisted in its oversight role by Internal Audit. Internal Audit undertakes both regular and ad hoc reviews of risk management controls and procedures, the results of which are reported to the Audit Committee. A. Risk management 1 Credit risk Credit risk is the risk of financial loss to the Group if a debtor or counterparty to a financial instrument fails to meet its contractual obligations, and arises mainly from the Company’s receivables. The Group restricts exposure to credit risk by investing only in bank deposits. The Group held cash and cash equivalents and short-term deposits of USD 15,339 thousand at December 31, 2023 (2022 – USD 31,682 thousand). These are held with banks, which are rated A2, based on Moody’s Rating Agency ratings. The short-term deposits, mainly in USD, bear fixed interest ranging between 1% - 5.4%. The carrying amount of cash and cash equivalents and short-term deposits approximate their fair value. As of December 31, 2023 the group has an amount of USD 139 thousand in short term deposits guaranteed for the Group’s leases and credit and am amount of USD 700 thousand in short term deposits guaranteed for hedging transactions. 2. Market risk Market risk is the risk that changes in market prices, such as foreign currency exchange rates, the CPI, interest rates and the prices of equity instruments, will influence the Group’s results or the value of its holdings in financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing returns. The Group hedges the foreign currency risk exposure that derives from salary expenses by means of foreign currency derivatives. In the framework of assessing whether the aforesaid hedging relationships qualify for hedge accounting, the Group applies the mandatory reliefs set forth in the amendments to IFRS 9 Financial Instruments Financial Instruments: Disclosures, Interest Rate Benchmark Reform Therefore, as at December 31, 2023 the Group is of the opinion that these hedging relationships continue to qualify for hedge accounting. Currency risk The Group is exposed to currency risk mainly for cash and purchases for research and development expenses that are denominated in NIS and EURO. Therefore, the Group is exposed to exchange rate fluctuations in these currencies against the dollar and takes steps to reduce the currency risk by maintaining its liquid resources in accordance with its future needs. Set forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2023: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 11 28 550 (28 ) (11 ) Other current assets 13 33 660 (33 ) (13 ) Accounts payable (5 ) (11 ) (225 ) 11 5 Other payables (27 ) (67 ) (1,340 ) 67 27 Post-employment benefit liabilities (3 ) (7 ) (141 ) 7 3 Total income (loss) (11 ) (24 ) 24 11 Set forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2023: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 1 2 48 (2 ) (1 ) Accounts payable (3 ) (8 ) (153 ) 8 3 Other payables (5 ) (12 ) (232 ) 12 5 Total income (loss) (7 ) (18 ) 18 7 Set forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2022: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 19 48 960 (48 ) (19 ) Other current assets 17 42 841 (42 ) (17 ) Accounts payable (4 ) (10 ) (205 ) 10 4 Other payables (33 ) (83 ) (1,668 ) 83 33 Post-employment benefit liabilities (3 ) (7 ) (145 ) 7 3 Total income (loss) (4 ) (10 ) 10 4 Set forth below is a sensitivity test to possible changes in USD/ EURO exchange rate as of December 31, 2022: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 45 112 2,246 (112 ) (45 ) Accounts payable (20 ) (49 ) (979 ) 49 20 Other payables (4 ) (10 ) (207 ) 10 4 Total income (loss) 21 53 (53 ) (21 ) B. Financial instruments measured at fair value: 1. In October 2021, the Company received a convertible note in the amount of $1.5 million and a warrant for 300 thousand Coeptis shares as part of Coeptis termination at an exercise price of $5 per warrant. As of December 31, 2023 the outstanding balance of the convertible note was $625 thousands. During January 2024, Coeptis paid an additional $0.2 million under the convertible note. The warrants are exercisable until September 21, 2024. This convertible debt instrument does not meet the solely payments of principal and i The fair value of these financial instruments as of December 31,2023 was measured at USD 73 thousand (2022- USD 431 thousand). 2. In October 2023, as part of a registered direct offering, the Company issued 4,347,827 warrants, and amended certain existing warrants to purchase up to an aggregate of 555,555 of the Company’s ADSs that were previously issued in June 2020 at exercise prices of $9.00 per ADS such that effective upon the closing of the offering the amended warrants will have a reduced exercise price of $1.25 per ADS and will expire five and a one-half years from the closing date of the offering. The warrants were classified as a non-current financial liability as they can be settled in cash on the occurrence of Fundamental Transaction as determined in the agreement. This liability was initially recognized at its fair value on the closing date of the offering and is subsequently accounted for fair value at each balance sheet date and recorded through profit and loss. The fair value of these financial instruments as of December 31,2023 was measured at USD 2,518 thousand 3. Fair value hierarchy of financial instruments measured at fair value: December 31, 2023 Level 1 Level 2 Level 3 Total USD thousands Financial asset and liabilities Convertible debt instrument and warrant (see Note 19B (1)) - - 73 73 Financial liability of warrants - - 2,518 2,518 December 31, 2022 Level 1 Level 2 Level 3 Total USD thousands Financial asset Convertible debt instrument and warrant (see Note 19B (1)) - - 431 431 Details regarding fair value measurement at Level 3: Financial asset- Financial liability- Balance as of January 1, 2023 431 - Issuance - 6,015 Proceed (875 ) - Revaluation 517 (3,497 ) Balance as of December 31, 2023 73 2,518 Financial instrument Valuation Significant For the year ended December 31, 2023 Warrant (see note 10D1) Black - Scholes expected term 5.3 years expected volatility 89.94 % annual risk free interest 3.88 % dividend yield 0 % Convertible debt instrument DLOM 26.1 % For the year ended December 31, 2022 Warrant Black - Scholes expected term 1.72 years expected volatility 117.42 % annual risk free interest 4.47 % dividend yield 0 % Convertible debt instrument DLOM 37.6 %

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 20 - Subsequent Events On February 6, 2024 the Company issued 816,827 ADSs due to an exercise of 816,827 October 2023 prefunded warrants (see Note 10D1).

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of consolidation	A. Basis of consolidation 1. Acquisition of Subsidiaries Upon acquisition of subsidiaries, the Company evaluates whether the acquisition is considered a business acquisition or an acquisition of an asset (or group of assets). If the Company reaches the conclusion that the subsidiary acquired is a considered a business, it accounts for business combinations using the acquisition method when control is transferred to the Group. The consideration transferred in the acquisition is generally measured at fair value, as are the identifiable net assets acquired. Transaction costs are expensed as incurred, except if related to the issue of debt or equity securities. If the acquired subsidiary is not considered a business, the Company accounts for the acquisition as a purchase of assets. The Company uses the optional concentration test to determine the accounting treatment of such acquisitions. In applying the concentration test, an entity determines whether substantially all the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If so, the asset is not considered a business. As of December 31, 2023, the acquisitions made by the Company were determined to be an acquisition of assets, see Note 5. Contingent considerations transferred for acquisition of subsidiaries are recorded when the terms and conditions for payment of the consideration are met. 2. Subsidiaries Subsidiaries are entities controlled by the Group. The financial statements of subsidiaries are included in the consolidated financial statements from the date on which control commences until the date on which control ceases. 3. Non-controlling interests Non-controlling interests that are instruments that give rise to a present ownership interest and entitle the holder to a share of net assets in the event of liquidation (for example: ordinary shares), are measured at the date of the business combination at fair value. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.
Foreign currency transactions	B. Foreign currency transactions Transactions in foreign currencies are translated to USD which is the functional currency of Group entities at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between its cost in the functional currency on date of translation, and the monetary cost in foreign currency translated at the exchange rate at the end of the year. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.
Financial instruments	C. Financial instruments 1. Non-derivative financial assets Initial recognition and measurement of financial assets The Group initially recognizes debt instruments issued on the date that they are created. All other financial assets are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. A financial asset is initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issuance of the financial asset. Subsequent measurement and gains and losses Financial assets at fair value through profit or loss These assets are subsequently measured at fair value. Net gains and losses, including any interest income, are recognized in profit or loss. 2. Non-derivative financial liabilities Non-derivative financial liabilities include: finance lease liabilities, accounts payables and other payables. Initial recognition of financial liabilities Financial liabilities are recognized initially on the trade date at which the Group becomes a party to the contractual provisions of the instrument. Financial liabilities (other than financial liabilities at fair value through profit or loss) are recognized initially at fair value less any directly attributable transaction costs. Subsequent measurement of financial liabilities Subsequent to initial recognition these financial liabilities are measured at amortized cost using the effective interest method. Derecognition of financial liabilities Financial liabilities are derecognized when the obligation of the Group, as specified in the agreement, expires or when it is discharged, cancelled or transferred to equity. 3. Derivative financial instruments As part of the October 2023 capital raising agreement, the Company issued new warrants and amended previous warrants that were classified as derivative financial instruments. Measurement of derivative financial instruments Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit or loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are accounted for as described below. The changes in fair value of these derivatives are recognized in profit or loss, as financing income or expense. The fair value of these derivatives is based on an evaluation and classified as level 3. 4. Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options are recognized as a deduction from equity. Incremental costs directly attributable to an expected issuance of an instrument that will be classified as an equity instrument are recognized as an asset in deferred expenses in the statement of financial position. The costs are deducted from equity upon the initial recognition of the equity instruments, or are amortized as financing expenses in the statement of income when the issuance is no longer expected to take place. 5. Issuance of parcel of securities The consideration received from the issuance of parcel of securities is attributed initially to financial liabilities that are measured each period at fair value through profit or loss, and then to financial liabilities that are measured only upon initial recognition at fair value. The remaining amount is allocated to equity. Direct issuance costs are attributed to the specific securities in respect of which they were incurred, whereas joint issuance costs are attributed to the securities on a proportionate basis according to the allocation of the consideration from the issuance of the units, as described above. As part of the October 2023 capital raising, the Company issued pre-funded warrants and amended terms for previous warrants. The Company classified the pre-funded warrants as an equity instrument due to their negligible exercise price. The amended terms for previously issued warrants increased the fair value of those warrants. The amended terms were part of the capital raising and therefore the Company accounted for the increase in value as issuance cost.
Intangible assets	D. Intangible assets 1. Research and development Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss when incurred. Development activities involves research for new or substantially improved drug candidates and processes, the manufacturing of such candidates and the pre-clinical and clinical studies for these candidates. Development expenditure are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Group has the intention and sufficient resources to complete development and to use or sell the asset. Currently all development costs are recognized in profit and loss as expense. 2. Other intangible assets Other intangible assets, including in-process research and development in respect of the Company’s acquisition of TyrNovo ,Famewave, Immunorizion, and asset purchased by Purple GmbH (see also Note 5), which have infinite useful lives, are measured at cost less accumulated impairment losses. 3. Amortization The Group examines the useful life of an intangible asset that is not periodically amortized at least once a year in order to determine whether events and circumstances continue to support the decision that the intangible asset has an indefinite useful life and if any impairment may be needed.
Impairment	E. Impairment Timing of impairment testing The carrying amounts of the Group’s non-financial assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. Once a year and on the same date, or more frequently if there are indications of impairment, the Group estimates the recoverable amount of each cash generating unit that contains intangible assets that have indefinite useful lives. Measurement of recoverable amount The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs of disposal. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects the assessments of market participants regarding the time value of money and the risks specific to the asset or cash-generating unit, for which the estimated future cash flows from the asset or cash-generating unit were not adjusted. Recognition of impairment loss An impairment loss is recognized if the carrying amount of an asset or cash-generating unit exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.
Loss per share	F. Loss per share The Group presents basic and diluted loss per share data for its ordinary share capital (including pre-funded warrants). Basic loss per share is calculated by dividing the loss attributable to holders of ordinary shares, by the weighted average number of ordinary shares outstanding during the year. The loss per share data is presented in the profit and loss statement as loss per ADS giving effect to the number of 10 shares per 1 ADS.
Employee benefits	G. Employee benefits The Group has a number of post-employment benefit plans. The plans are usually financed by deposits with insurance and pension companies, and they are classified as defined contribution plans and as defined benefit plans. A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further amounts. Obligations for contributions to defined contribution pension plans are recognized as an expense in profit or loss in the periods during which related services are rendered by employees. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognized for the amount expected to be paid under short-term cash bonus if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.
Share-based payment transactions	H. Share-based payment transactions The grant date fair value of share-based payment awards granted to employees is recognized as a salary expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards. The amount recognized as an expense in respect of share-based payment awards that are conditional upon meeting service and non-market performance conditions, is adjusted to reflect the number of awards that are expected to vest.
Provisions	I. Provisions A provision is recognized if, as a result of a past event, the Group has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. A provision for legal claims is recognized if, as a result of a past event, the Company has a present legal or constructive obligation and it is more likely than not that an outflow of economic benefits will be required to settle the obligation and the amount of obligation can be estimated reliably.
Financing income and expense	J. Financing income and expense Finance income comprises changes in the fair value of the financial liability through profit and loss, gains on changes in the fair value of financial assets at fair value through profit or loss and income from short- term and long-term deposits, foreign currency gains, and the reclassification of net gains and losses previously recognized in other comprehensive income on cash flow hedges of foreign currency. Finance expenses include loss from exchange rate differences and interest fee. Interest income or expense is recognized, using the effective interest method. In the statements of cash flows, interest received is presented as part of cash flows from investing activities and interest paid is presented as part of cash flows from financing activities.
Income tax expense	K. Income tax expense Income tax comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that they relate to a business combination, or are recognized directly in equity or in other comprehensive income. Deferred tax asset is recognized for unused tax losses, tax benefits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. The Company has not recognized deferred tax assets as no future taxable profits are expected in the foreseeable future.
Leases	L. Leases Leased assets and lease liabilities Contracts that award the Group control over the use of a leased asset for a period of time in exchange for consideration, are accounted for as leases. Upon initial recognition, the Group recognizes a liability at the present value of the balance of future lease payments (these payments do not include certain variable lease payments), and concurrently recognizes a right-to-use asset at the same amount of the lease liability, adjusted for any prepaid or accrued lease payments, plus initial direct costs incurred in respect of the lease. Since the interest rate implicit in the Group’s leases is not readily determinable, the incremental borrowing rate of the lessee is used. Subsequent to initial recognition, the right-to-use asset is accounted for using the cost model, and depreciated over the shorter of the lease term or useful life of the asset. The lease term The lease term is the non-cancellable period of the lease plus periods covered by an extension or termination option if it is reasonably certain that the lessee will or will not exercise the option, respectively. Depreciation of right-to-use asset After lease commencement, a right-to-use asset is measured on a cost basis less accumulated depreciation and accumulated impairment losses and is adjusted for re-measurements of the lease liability. Depreciation is calculated on a straight-line basis over contractual lease period as follows: office lease from September 15 2020 for 5 years and 3.5 months.
Discontinued operations	M. Discontinued operations A discontinued operation is a component of the Group’s business that represents a separate major line of business that has been disposed of or is held for sale or distribution. Classification as a discontinued operation occurs upon disposal or when the operation meets the criteria to be classified as held for sale, if earlier. When an operation is classified as a discontinued operation, the comparative statement of operation is restated as if the operation had been discontinued from the start of the earliest comparative period.

Basis of Preparation of the C_2

Basis of Preparation of the Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2023
Basis of Preparation of the Consolidated Financial Statements [Abstract]
Schedule of Adjustment to Carrying Amounts of Assets and Liabilities	Information about assumptions made by the Group with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in the following notes: Estimate Principal assumptions Possible effects Reference Assessment of probability of contingent liabilities Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees Reversal or creation of a provision for a claim For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities Recoverability of intangible assets The discounted cash flows method includes assumptions such as future expenses, future revenues, success rates (in respect of transition between phases of the R&D of the clinical trials until reaching regulatory approval and marketing) and discount rate. Impairment of the in-process research and development in profit or loss See Note 5 regarding Intangible assets
Schedule of Data on Exchange Rates	Data on exchange rates are as follows: Representative exchange rate (NIS/USD 1) Date of consolidated financial statements: December 31, 2023 3.627 December 31, 2022 3.519 December 31, 2021 3.110 % Changes in exchange rates for the year ended: December 31, 2023 3 December 31, 2022 13 December 31, 2021 (3 )

Discontinued Operation (Tables)

Discontinued Operation (Tables)	12 Months Ended
	Dec. 31, 2023
Discontinued Operation [Abstract]
Schedule of Discontinued Operation	Consensi represented a separate major line of business. Discontinuation also included inventory write off. Consequently, the Company reported Consensi as a discontinued operation and as of December 31, 2021 has one operating segment- oncology. 2021 USD thousands Results of discontinued operation Revenue - Expenses 642 Loss for the year 642 Loss for the year attributable to the owners of the Company: From continuing operations 17,826 From discontinued operation 642 Loss per share – Discontinued operation Basic & diluted loss per ADS – USD 0.04 Cash flows from discontinued operation Net cash used in operating activities (374 )

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Intangible Assets [Abstract]
Schedule of Intangible Assets	As of December 31, 2023, and 2022: 2023 2022 USD thousands IPR&D related to TyrNovo (see 5A below) 6,172 6,172 IPR&D related to Famewave (see 5B below) 14,310 14,310 IPR&D related to Immunorizon (see 5C below) 7,360 - IPR&D related to Purple GmbH 202 202 Total intangible assets 28,044 20,684
Schedule of Recognized Amounts Assets Acquired and Liabilities Assumed	The following table summarizes the recognized amounts of assets acquired and liabilities assumed at the date of acquisition: USD thousands Cash 44 Intangible asset (1) 7,360 Other receivables 1 Trade payables (28 ) Other payables (2 ) Total net identifiable assets 7,375 (1) Intangible asset - In process research and development The fair value of the intangible asset recognized at the acquisition date was determined according to the fair value of the issued equity (2,215,190 ADSs) which amounted to USD 3,781 thousand and the cash paid. According to the agreement, the equity issued included a price protection mechanism as well as a lock up period of three months. The fair value of equity issued was based on the assumptions below:

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2023
Cash and Cash Equivalents [Abstract]
Schedule of Cash and Cash Equivalents	As of December 31, 2023 2022 USD thousands Balance in USD 14,007 11,902 Balance in other currencies 482 3,128 Total cash and cash equivalents 14,489 15,030

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of Carrying Amounts of Right-to-Use Assets	Carrying amounts of right-to-use assets and change during the period: Office lease USD thousands Balance as of January 1, 2023 467 Depreciation on right-to-use assets (151 ) Balance as of December 31, 2023 316 Balance as of January 1, 2022 619 Depreciation on right-to-use assets (152 ) Balance as of December 31, 2022 467
Schedule of Maturity Analysis of the Company's Lease Liabilities	Maturity analysis of the Company’s lease liabilities December 31, December 31, 2023 2022 USD thousands USD thousands Less than one year 188 204 One to two years 188 388 Total 376 592 Current maturities of lease liability 188 194 Long-term lease liability 163 321
Schedule of Amounts Recognized in Profit or Loss	Amounts recognized in profit or loss 2023 2022 USD thousands USD thousands Interest expenses on lease liability 37 49

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Other Current Assets [Abstract]
Schedule of Other Current Assets	As of December 31, 2023 2022 USD thousands Government authorities 171 146 Prepaid expenses and other receivables 205 997 Total other current assets 376 1,143

Other Payables (Tables)

Other Payables (Tables)	12 Months Ended
	Dec. 31, 2023
Other Payables [Abstract]
Schedule of Other Payables	As of December 31, 2023 2022 USD thousands Due to related parties - salary related 620 607 Accrued expenses 2,521 3,597 Government authorities 53 81 Salary related 269 437 Other payables - 10 3,463 4,732

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2023
Equity [Abstract]
Schedule of Share Capital	The Company’s share capital As of December 31, As of December 31, Number of shares in thousands Authorized Issued and Authorized Issued and Shares, no par value 1,000,000 252,379 1,000,000 184,815 Class A preferred shares, no par value 10,000 - 10,000 - Class B preferred shares, no par value 10,000 - 10,000 - Class C preferred shares, no par value 10,000 - 10,000 - Class D preferred shares, no par value 10,000 - 10,000 - Class E preferred shares, no par value 10,000 - 10,000 -
Schedule of Changes in Share Capital	Changes in share capital during the year For the year ended December 31 2023 2022 2021 Number of ADSs in thousands Issued as at January 1 18,482 17,800 17,211 Issuance of ADSs (See D below and 5C) 6,388 544 126 Vesting of RSUs 368 138 163 Exercise of warrants - - 300 Issued as at December 31 25,238 18,482 17,800
Schedule of the Information Relating to Non-Controlling Interests	The following table summarizes the information relating to Tyrnovo that has non-controlling interests of 1.53%, before any intra-group eliminations: December 31, December 31, TyrNovo Ltd. in USD thousands Non-current assets 6 10 Current assets 247 428 Current liabilities (23,419 ) (17,240 ) Net assets (23,166 ) (16,802 ) Net assets attributable to non-controlling interests (355 ) (258 ) Loss for the year 6,365 5,983 Loss allocated to non-controlling interests 97 92

Share-Based Payment Arrangeme_2

Share-Based Payment Arrangements (Tables)	12 Months Ended
	Dec. 31, 2023
Share-based Payment Arrangements [Abstract]
Schedule of Number and Weighted Average Exercise Prices of Share Options	The number and weighted average exercise prices (in USD) of share options are as follows: Weighted average exercise price Number of options 2023 2022 2021 2023 2022 2021 Outstanding on January 1 0.52 0.97 1.02 18,468,235 7,751,303 6,994,377 Expired and forfeited during the year 0.54 0.82 1.52 (2,026,452 ) (418,068 ) (413,074 ) Granted during the year 0.19 0.28 0.47 2,777,000 11,135,000 1,170,000 Outstanding on December 31 0.46 0.52 0.97 19,218,782 18,468,235 7,751,303 Exercisable on December 31 0.62 0.97 1.48 10,923,032 6,144,318 4,451,430
Schedule of Number of RSUs	The number of RSUs are as follows: Number of RSUs 2023 2022 Outstanding at January 1 7,857,917 2,610,000 Granted during the year 2,777,000 6,785,000 Forfeited during the year (1,187,292 ) (157,083 ) Vested during the year (3,676,875 ) (1,380,000 ) Outstanding at December 31 5,770,750 7,857,917
Schedule of Assumptions were Used	The following assumptions were used : 2023 2022 Share Price - USD 0.160-0.226 0.213-0.316 Exercise price - USD 0.19-0.2 0.208-0.304 Expected volatility (%) 93.54-96.04 91.64-96.26 Expected duration (years) 2-5 2-5 Dividend yield (%) - - Risk free rate interest rate (%) 3.56%-4.31% 2.90%-4.28%
Schedule of Expenses Recognized in the Consolidated Financial Statements	Expenses recognized in the consolidated financial statements: For the year ended 2023 2022 2021 USD thousands Research and development expenses 768 768 557 General and administrative expenses 1,107 1,644 1,525 Total share-based expense recognized 1,875 2,412 2,082

Transactions and Balances wit_2

Transactions and Balances with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2023
Transactions and Balances with Related Parties [Abstract]
Schedule of Recorded Expenses to Executive Officers	The Company recorded expenses to executive officers: For the year ended December 31 2023 2022 2021 USD thousands Short - term employee benefits 2,066 2,623 2,402 Post-employment benefits 12 11 27 Share based payments 1,346 1,930 1,446 3,424 4,564 3,875 For the year ended December 31 2023 2022 2021 USD thousands Short - term benefits 427 448 323 Share based payments 284 311 478 711 759 801

Research and Development Expe_2

Research and Development Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Research and Development Expenses [Abstract]
Schedule of Research and Development Expenses	For the year ended December 31 2023 2022 2021 USD thousands Salaries, wages and related expenses 2,323 2,382 1,721 Share-based payments (see also Note 11) 768 768 557 Service providers 13,943 13,170 9,549 17,034 16,320 11,827

Sales, General and Administra_2

Sales, General and Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Sales, General and Administrative Expenses [Abstract]
Schedule of Sales, General and Administrative Expenses	For the year ended December 31 2023 2022 2021 USD thousands Salaries, wages and related expenses 1,769 1,845 1,762 Share-based payments (see also Note 11) 822 1,333 1,047 Legal fees in connection with ISA investigation and class action lawsuits (see also Note 13B) - 135 12 Reimbursement of legal fees (116 ) (63 ) (66 ) Other professional fees 1,004 750 1,222 Board member remuneration and insurance 818 1,152 1,033 Board member share-based payments 284 311 478 Maintenance expenses 196 120 55 Travel and car expenses 130 144 133 Depreciation 199 201 231 Other 131 355 200 5,237 6,283 6,107

Finance Expense (Income), Net (

Finance Expense (Income), Net (Tables)	12 Months Ended
	Dec. 31, 2023
Finance Expense (Income), Net [Abstract]
Schedule of Finance Expenses and Income	Finance expenses and income For the year ended December 31 2023 2022 2021 USD thousands Finance expenses Fees and interest expense 56 67 79 Loss from exchange rate differences, net 13 - 133 Issuance expenses (see note 10D) 2,126 - - 2,195 67 212 For the year ended December 31 2023 2022 2021 USD thousands Finance income Interest income from deposits (474 ) (532 ) (320 ) Income from exchange rate differences, net - (62 ) - Changes in fair value of finance instruments (517 ) (245 ) - Other (1 ) (71 ) - (992 ) (910 ) (320 )

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2023
Employee Benefits [Abstract]
Schedule of Post-Employee Benefits	Employee benefits include post-employment benefits and short-term benefits. For the Year ended 2023 2022 USD thousands USD thousands Short-term benefits 549 463 Post-employment benefit liabilities 141 145 Post-employment benefit liabilities included in other payables - 158
Schedule of Defined Contribution Plan in Respect of its Employees	The Company has a defined contribution plan in respect of the Company’s liability in respect of its employees who are subject to Section 14 of the Severance Pay Law – 1963. For the Year ended December 31 2023 2022 2021 USD thousands USD thousands USD thousands Amount recognized as expense in respect of defined contribution plan 401 390 291

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Financial Instruments (Tables) [Line Items]
Schedule of Details Regarding Fair Value Measurement	Fair value hierarchy of financial instruments measured at fair value: December 31, 2023 Level 1 Level 2 Level 3 Total USD thousands Financial asset and liabilities Convertible debt instrument and warrant (see Note 19B (1)) - - 73 73 Financial liability of warrants - - 2,518 2,518 December 31, 2022 Level 1 Level 2 Level 3 Total USD thousands Financial asset Convertible debt instrument and warrant (see Note 19B (1)) - - 431 431
Schedule of Details Regarding Fair Value Measurement	Financial asset- Financial liability- Balance as of January 1, 2023 431 - Issuance - 6,015 Proceed (875 ) - Revaluation 517 (3,497 ) Balance as of December 31, 2023 73 2,518
Schedule of Fair Value Measurement	Details regarding fair value measurement at Level 3: Financial instrument Valuation Significant For the year ended December 31, 2023 Warrant (see note 10D1) Black - Scholes expected term 5.3 years expected volatility 89.94 % annual risk free interest 3.88 % dividend yield 0 % Convertible debt instrument DLOM 26.1 % For the year ended December 31, 2022 Warrant Black - Scholes expected term 1.72 years expected volatility 117.42 % annual risk free interest 4.47 % dividend yield 0 % Convertible debt instrument DLOM 37.6 %
Currency risk [Member]
Financial Instruments (Tables) [Line Items]
Schedule of Sensitivity Test to Possible Changes in Exchange Rate	Set forth below is a sensitivity test to possible changes in USD/NIS exchange rate as of December 31, 2023: Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 11 28 550 (28 ) (11 ) Other current assets 13 33 660 (33 ) (13 ) Accounts payable (5 ) (11 ) (225 ) 11 5 Other payables (27 ) (67 ) (1,340 ) 67 27 Post-employment benefit liabilities (3 ) (7 ) (141 ) 7 3 Total income (loss) (11 ) (24 ) 24 11 Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 1 2 48 (2 ) (1 ) Accounts payable (3 ) (8 ) (153 ) 8 3 Other payables (5 ) (12 ) (232 ) 12 5 Total income (loss) (7 ) (18 ) 18 7 Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 19 48 960 (48 ) (19 ) Other current assets 17 42 841 (42 ) (17 ) Accounts payable (4 ) (10 ) (205 ) 10 4 Other payables (33 ) (83 ) (1,668 ) 83 33 Post-employment benefit liabilities (3 ) (7 ) (145 ) 7 3 Total income (loss) (4 ) (10 ) 10 4 Sensitive instrument Income (loss) from Value Income (loss) from Down 2% Down 5% Up 5% Up 2% Cash and cash equivalents and deposits 45 112 2,246 (112 ) (45 ) Accounts payable (20 ) (49 ) (979 ) 49 20 Other payables (4 ) (10 ) (207 ) 10 4 Total income (loss) 21 53 (53 ) (21 )

General (Details)

General (Details) - USD ($) $ in Millions		1 Months Ended			12 Months Ended
	Jan. 07, 2020	Feb. 28, 2023	Aug. 23, 2020	Jan. 31, 2020	Dec. 31, 2023
General [Abstract]
American depository ordinary shares			10
Warrants shares					10
American depository shares purchase					1
Contract to acquire, percentage	100%	100%		100%
Retained earnings (in Dollars)					$ 137.4
Net of issuance expenses (in Dollars)					$ 101.5

Basis of Preparation of the C_3

Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of Adjustment to Carrying Amounts of Assets and Liabilities	12 Months Ended
	Dec. 31, 2023
Principal assumptions [Member]
Schedule of Adjustment to Carrying Amounts of Assets and Liabilities [Line Items]
Assessment of probability of contingent liabilities	Whether it is more likely than not that an outflow of economic resources will be required in respect of legal claims pending against the Company and its investees
Recoverability of intangible assets	The discounted cash flows method includes assumptions such as future expenses, future revenues, success rates (in respect of transition between phases of the R&D of the clinical trials until reaching regulatory approval and marketing) and discount rate.
Possible effects [Member]
Schedule of Adjustment to Carrying Amounts of Assets and Liabilities [Line Items]
Assessment of probability of contingent liabilities	Reversal or creation of a provision for a claim
Recoverability of intangible assets	Impairment of the in-process research and development in profit or loss
Reference [Member]
Schedule of Adjustment to Carrying Amounts of Assets and Liabilities [Line Items]
Assessment of probability of contingent liabilities	For information on the Company’s exposure to claims see Note 13B regarding contingent liabilities
Recoverability of intangible assets	See Note 5 regarding Intangible assets

Basis of Preparation of the C_4

Basis of Preparation of the Consolidated Financial Statements (Details) - Schedule of Data on Exchange Rates	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Data on Exchange Rates [Abstract]
Representative exchange rate of USD	3.627	3.519	3.11
Changes in exchange rates for the year ended:
Representative exchange rate, percentage	3	13	(3)

Material Accounting Policies (D

Material Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2023
Material Accounting Policies [Abstract]
Lease term	5 years

Discontinued Operation (Details

Discontinued Operation (Details)	12 Months Ended
	Dec. 31, 2021
Discontinued Operation [Abstract]
Number of operating segment	1

Discontinued Operation (Detai_2

Discontinued Operation (Details) - Schedule of Discontinued Operation - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Results of discontinued operation
Revenue
Expenses			642
Loss for the year			642
Loss for the year attributable to the owners of the Company:
From continuing operations	19,977	21,760	17,826
From discontinued operation			$ 642
Loss per share – Discontinued operation
Basic & diluted loss per ADS – USD (in Dollars per share)			$ 0.04
Net cash used in operating activities			$ (374)

Discontinued Operation (Detai_3

Discontinued Operation (Details) - Schedule of Discontinued Operation (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Discontinued Operation [Abstract]
Diluted loss per ADS – USD			$ 0.04

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)		1 Months Ended			12 Months Ended
	Jan. 07, 2020	Feb. 28, 2023	Jan. 31, 2020	Dec. 31, 2019	Dec. 31, 2023
Intangible Assets [Abstract]
Direct ownership of equity				98.47%
Contract to acquire percentage	100%	100%	100%
Acquisition of famewave description					the Company completed the acquisition of 100% of Immunorizon Ltd, a privately held biopharmaceutical Company developing potential multispecific T and NK cell engager oncology therapies that selectively activate the immune response within the tumor microenvironment, (“Immunorizon”) from its shareholders in consideration of an aggregate upfront payment of $3.5 million in cash, an aggregate of $3.5 million in ADSs (or 2,215,190 ADSs representing ordinary shares at a price per ADS equal to the NASDAQ volume-weighted average price of the Company’s ADSs for the 60-day period preceding the execution date of the agreement) with three months lock up period including a price protection mechanism for 12 months (see Note 10D1). Additional future considerations include future payments when achieving certain long-term milestones set at an aggregate amount of $94 million, including royalties on net sales. The acquisition closed on February 15, 2023. The total acquisition amounted to $ 3.6 million.
Issued equity (in Dollars)					$ 2,215,190
Fair value of the issued equity (in Dollars)					$ 3,781,000
Share price (in Dollars per share)					$ 1.59
Expected volatility					70.89%
Annual risk-free rate					4.50%
Dividend yield					0%
Percentage of discount for lack of marketability					10.80%
Intangible assets recoverable amount percentage					18.90%

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of Intangible Assets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Intangible Assets [Line Items]
Total intangible assets	$ 28,044	$ 20,684
IPR&D related to TyrNovo (see 5A below) [Member]
Schedule of Intangible Assets [Line Items]
Total intangible assets	6,172	6,172
IPR&D related to Famewave (see 5B below) [Member]
Schedule of Intangible Assets [Line Items]
Total intangible assets	14,310	14,310
IPR&D related to Immunorizon (see 5C below) [Member]
Schedule of Intangible Assets [Line Items]
Total intangible assets	7,360
IPR&D related to Purple GmbH [Member]
Schedule of Intangible Assets [Line Items]
Total intangible assets	$ 202	$ 202

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of Recognized Amounts Assets Acquired and Liabilities Assumed $ in Thousands	Dec. 31, 2023 USD ($)
Intangible Assets [Abstract]
Cash	$ 44
Intangible asset	7,360	[1]
Other receivables	1
Trade payables	(28)
Other payables	(2)
Total net identifiable assets	$ 7,375
[1] Intangible asset - In process research and development The fair value of the intangible asset recognized at the acquisition date was determined according to the fair value of the issued equity (2,215,190 ADSs) which amounted to USD 3,781 thousand and the cash paid.

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 14,489	$ 15,030	$ 10,890	$ 11,247
Balance in USD [Member]
Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents	14,007	11,902
Balance in other currencies [Member]
Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents [Line Items]
Total cash and cash equivalents	$ 482	$ 3,128

Leases (Details)

Leases (Details) $ in Thousands	Sep. 15, 2020 USD ($)
Leases (Details) [Line Items]
Agreement lease term	5 years
Lease liability and right-of-use asset (in Dollars)	$ 817
Percentage of current terms	5%
Rehovot [Member]
Leases (Details) [Line Items]
Agreement lease term	5 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of Carrying Amounts of Right-to-Use Assets - Office lease [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases (Details) - Schedule of Carrying Amounts of Right-to-Use Assets [Line Items]
Balance at beginning	$ 467	$ 619
Depreciation on right-to-use assets	(151)	(152)
Balance at ending	$ 316	$ 467

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Maturity Analysis of the Company's Lease Liabilities - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Maturity Analysis of the Company [Line Items]
Total	$ 376	$ 592
Current maturities of lease liability	188	194
Long-term lease liability	163	321
Less than one year [Member]
Schedule of Maturity Analysis of the Company [Line Items]
Total	188	204
One to two years [Member]
Schedule of Maturity Analysis of the Company [Line Items]
Total	$ 188	$ 388

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Amounts Recognized in Profit or Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Interest expenses on lease liability	$ 37	$ 49

Other Current Assets (Details)

Other Current Assets (Details) - Schedule of Other Current Assets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Current Assets [Abstract]
Government authorities	$ 171	$ 146
Prepaid expenses and other receivables	205	997
Total other current assets	$ 376	$ 1,143

Other Payables (Details) - Sche

Other Payables (Details) - Schedule of Other Payables - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Payables [Abstract]
Due to related parties - salary related	$ 620	$ 607
Accrued expenses	2,521	3,597
Government authorities	53	81
Salary related	269	437
Other payables		10
Other Payables, Total	$ 3,463	$ 4,732

Equity (Details)

Equity (Details) - USD ($)				1 Months Ended		12 Months Ended
	Oct. 19, 2023	Oct. 17, 2023	Mar. 23, 2022	Oct. 31, 2023	Oct. 19, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 30, 2020
Equity (Details) [Line Items]
Ordinary shares (in Shares)						1,000,000,000
Non-voting senior preferred shares (in Shares)						50,000,000
Preferred shares (in Shares)						10,000,000
Company funds raised						$ 1,560,000	$ 1,490,000	$ 560,000
Placement agent fees and other offering related expenses						1,500,000	1,440,000	540,000
Public offering issued price (in Dollars per share)									$ 9
Issue of equity						$ 1,495,000	$ 1,346,000	$ 540,000
Warrants to purchase shares (in Shares)						3,680	1,380,000	1,634,000
Warrant term, description	an extended term of five and a half years from the closing of the offering					The October 2023 warrants have a term of five and a half years and have an exercise price of USD 1.25 per ADS
Exercise price (in Dollars per share)	$ 1.25			$ 1.25
Issuance expenses						$ 761,000
Prospectus amount			$ 50,000,000
Aggregate offering price		$ 3,000,000	$ 21,000,000
Sales agreement (in Shares)						1,044,040	543,400	126,160
Average price (in Dollars per share)						$ 1.63	$ 2.65	$ 4.46
Non-controlling interests						1.53%
Private Placement [Member]
Equity (Details) [Line Items]
Company funds raised	$ 5,000,000				$ 5,000,000
Top of range [member]
Equity (Details) [Line Items]
Exercise price (in Dollars per share)						$ 0.226	$ 0.316
Ads [Member]
Equity (Details) [Line Items]
Warrants term	5 years
Ads [Member] | Private Placement [Member]
Equity (Details) [Line Items]
Placement agent fees and other offering related expenses					4,300,000
Ads [Member] | Top of range [member]
Equity (Details) [Line Items]
Exercise price (in Dollars per share)	$ 9,000
Ads [Member] | Maximum [Member]
Equity (Details) [Line Items]
Exercise price (in Dollars per share)	$ 28
Warrants [member]
Equity (Details) [Line Items]
Company funds raised	$ 304,348,000				$ 304,348,000
Placement agent fees and other offering related expenses	$ 357,000
Exercise price (in Dollars per share)	$ 1.4375
Warrants [member] | Ads [Member]
Equity (Details) [Line Items]
Warrants to purchase shares (in Shares)	631,556
Public offering [Member] | Ads [Member]
Equity (Details) [Line Items]
Aggregate shares (in Shares)					2,430,000
Public offering issued price (in Dollars per share)	$ 1.15				$ 1.15
Issue of equity					$ 1,917,827
Warrants to purchase shares (in Shares)				699,495	4,347,827
Warrants fair value					$ 5,348,000

Equity (Details) - Schedule of

Equity (Details) - Schedule of Share Capital - shares shares in Thousands	Dec. 31, 2023	Dec. 31, 2022
Ordinary Share [Member]
Equity (Details) - Schedule of Share Capital [Line Items]
Number of shares, Authorized	1,000,000	1,000,000
Number of shares, Issued and paid-in	252,379	184,815
Class A Preferred Shares [Member]
Equity (Details) - Schedule of Share Capital [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class B Preferred Shares [Member]
Equity (Details) - Schedule of Share Capital [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class C Preferred Shares [Member]
Equity (Details) - Schedule of Share Capital [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class D Preferred Shares [Member]
Equity (Details) - Schedule of Share Capital [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in
Class E Preferred Shares [Member]
Equity (Details) - Schedule of Share Capital [Line Items]
Number of shares, Authorized	10,000	10,000
Number of shares, Issued and paid-in

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of Changes in Share Capital - shares shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Changes in Share Capital [Abstract]
Issued as at January 1	18,482	17,800	17,211
Issuance of ADSs (See D below and 5C)	6,388	544	126
Vesting of RSUs	368	138	163
Exercise of warrants			300
Issued as at December 31	25,238	18,482	17,800

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of the Information Relating to Non-Controlling Interests - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of the Information Relating to Non-Controlling Interests [Abstract]
Non-current assets	$ 6	$ 10
Current assets	247	428
Current liabilities	(23,419)	(17,240)
Net assets	(23,166)	(16,802)
Net assets attributable to non-controlling interests	(355)	(258)
Loss for the year	6,365	5,983
Loss allocated to non-controlling interests	$ 97	$ 92

Share-Based Payment Arrangeme_3

Share-Based Payment Arrangements (Details) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended					12 Months Ended
	Mar. 02, 2023	Jul. 11, 2022	Nov. 07, 2021	Jun. 07, 2021	Apr. 24, 2023	Oct. 31, 2022	Jun. 23, 2022	May 23, 2022	Aug. 31, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangements [Line Items]
Stock option granted	$ 45	$ 3,750			$ 2,732	$ 750		$ 6,635
Purchase the equilent of ADSs	4,500				273
Purchase the equivalent ADSs	$ 4,500				$ 273
Options exercise price (in Dollars per share)		$ 0.245			$ 0.19	$ 0.208				$ 0.19	$ 0.208	$ 0.346
Option exercise ordinary share (in Shares)	1	1	1	1	1	1	1	1	1
American shares (in Shares)										10
Option outstanding										$ 6	$ 6	$ 6
Weighted average contractual life										3 years 1 month 6 days	3 years 10 months 13 days	3 years 10 months 24 days
Board of Directors [Member]
Share-Based Payment Arrangements [Line Items]
Stock option granted			$ 112	$ 638					$ 420
Options exercise price (in Dollars per share)	$ 0.198		$ 0.47	$ 0.47					$ 0.492
Exercisable period	5 years	5 years	5 years		5 years	5 years		5 years
Officer [Member]
Share-Based Payment Arrangements [Line Items]
Options exercise price (in Dollars per share)								$ 0.304
Exercisable period				5 years					5 years
Consultant per shares (in Dollars per share)							$ 0.276
RSUs [Member]
Share-Based Payment Arrangements [Line Items]
Stock option granted		$ 150				$ 750
Fair value of options and grants measured		$ 591				$ 267
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangements [Line Items]
Stock option granted	$ 45				$ 2,732
Share Based Payment Arrangements [Member]
Share-Based Payment Arrangements [Line Items]
Stock option granted								$ 5,885
American shares (in Shares)										10
Share Based Payment Arrangements [Member] | Board of Directors [Member]
Share-Based Payment Arrangements [Line Items]
Vesting period	3 years	3 years	3 years	3 years	3 years	3 years		3 years	3 years
Fair value of options and grants measured	$ 16		$ 73	$ 406	$ 729			$ 3,237	$ 268
Share Based Payment Arrangements [Member] | New Director [Member]
Share-Based Payment Arrangements [Line Items]
Stock option granted			$ 112
Share Based Payment Arrangements [Member] | Officer and Employee [Member]
Share-Based Payment Arrangements [Line Items]
Stock option granted				$ 488					$ 420

Share-Based Payment Arrangeme_4

Share-Based Payment Arrangements (Details) - Schedule of Number and Weighted Average Exercise Prices of Share Options	12 Months Ended
	Dec. 31, 2023 $ / shares	Dec. 31, 2022 $ / shares	Dec. 31, 2021 $ / shares
Share-based Payment Arrangements [Abstract]
Weighted average exercise price, Outstanding beginning balance	$ 0.52	$ 0.97	$ 1.02
Number of options, Outstanding beginning balance	18,468,235	7,751,303	6,994,377
Weighted average exercise price, Exercisable	$ 0.62	$ 0.97	$ 1.48
Number of options, Exercisable	10,923,032	6,144,318	4,451,430
Weighted average exercise price, Expired and forfeited during the year	$ 0.54	$ 0.82	$ 1.52
Number of options, Expired and forfeited during the year	(2,026,452)	(418,068)	(413,074)
Weighted average exercise price, Granted during the year	$ 0.19	$ 0.28	$ 0.47
Number of options, Granted during the year	2,777,000	11,135,000	1,170,000
Weighted average exercise price, Outstanding ending balance	$ 0.46	$ 0.52	$ 0.97
Number of options, Outstanding ending balance	19,218,782	18,468,235	7,751,303

Share-Based Payment Arrangeme_5

Share-Based Payment Arrangements (Details) - Schedule of Number of RSUs	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Number of RSUs [Abstract]
Outstanding at beginning	7,857,917	2,610,000
Granted during the year	2,777,000	6,785,000
Forfeited during the year	(1,187,292)	(157,083)
Vested during the year	(3,676,875)	(1,380,000)
Outstanding at ending	5,770,750	7,857,917

Share-Based Payment Arrangeme_6

Share-Based Payment Arrangements (Details) - Schedule of Assumptions were Used - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Bottom of range [Member]
Share-Based Payment Arrangements (Details) - Schedule of Assumptions were Used [Line Items]
Share Price - USD	$ 0.16	$ 0.213
Exercise price - USD	$ 0.19	$ 0.208
Expected volatility (%)	93.54%	91.64%
Expected duration (years)	2 years	2 years
Risk free rate interest rate (%)	3.56%	2.90%
Top of range [Member]
Share-Based Payment Arrangements (Details) - Schedule of Assumptions were Used [Line Items]
Share Price - USD	$ 0.226	$ 0.316
Exercise price - USD	$ 0.2	$ 0.304
Expected volatility (%)	96.04%	96.26%
Expected duration (years)	5 years	5 years
Risk free rate interest rate (%)	4.31%	4.28%

Share-Based Payment Arrangeme_7

Share-Based Payment Arrangements (Details) - Schedule of Expenses Recognized in the Consolidated Financial Statements - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based expense recognized	$ 1,875	$ 2,412	$ 2,082
Research and development expenses [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based expense recognized	768	768	557
General and administrative expenses [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Total share-based expense recognized	$ 1,107	$ 1,644	$ 1,525

Transactions and Balances wit_3

Transactions and Balances with Related Parties (Details)	12 Months Ended
	Dec. 31, 2023
Transactions and Balances with Related Parties [Abstract]
Monthly fee and service, description	the Company pays the chairman of the board a monthly fee for his service as the chairman of our medical and clinical committee, and a monthly fee to one of the directors who has been engaged as an advisor in a 50% capacity.

Transactions and Balances wit_4

Transactions and Balances with Related Parties (Details) - Schedule of Recorded Expenses to Executive Officers - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Executive Officers [Member]
Transactions and Balances with Related Parties (Details) - Schedule of Recorded Expenses to Executive Officers [Line Items]
Short - term employee benefits	$ 2,066	$ 2,623	$ 2,402
Post-employment benefits	12	11	27
Share based payments	1,346	1,930	1,446
Total	3,424	4,564	3,875
Directors [Member]
Transactions and Balances with Related Parties (Details) - Schedule of Recorded Expenses to Executive Officers [Line Items]
Short - term employee benefits	427	448	323
Share based payments	284	311	478
Total	$ 711	$ 759	$ 801

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details)									12 Months Ended
	Nov. 07, 2022 USD ($)	Nov. 07, 2022 ILS (₪)	May 31, 2018 USD ($)	May 31, 2018 ILS (₪)	Nov. 08, 2016 USD ($)	Nov. 08, 2016 ILS (₪)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 ILS (₪)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 ILS (₪)
Commitments and Contingent Liabilities [Line Items]
Damages for motion			$ 354	₪ 1,100,000	$ 284	₪ 1,000,000	$ 4,600,000	₪ 16,400,000
Claim for court fee			$ 213,000	₪ 750,000
Gains on litigation settlements	$ 2,500	₪ 9,000,000							$ 8,200,000	₪ 29,000,000
Bottom of Range [member]
Commitments and Contingent Liabilities [Line Items]
Annual interest rate of revenues									3%	3%
Top of Range [member]
Commitments and Contingent Liabilities [Line Items]
Annual interest rate of revenues									6%	6%
TryNovo's Technologies [Member]
Commitments and Contingent Liabilities [Line Items]
Royalty payable									$ 1,520,000	₪ 5,500,000
Yissum’s Licensed Technology [Member]
Commitments and Contingent Liabilities [Line Items]
Annual interest rate of revenues									3%	3%
Percentage of sublicense consideration									12%	12%
Percentage of exit fee									12%	12%
THM [Member]
Commitments and Contingent Liabilities [Line Items]
Percentage of sublicense consideration									20%	20%
Percentage of exit fee									3.50%	3.50%
Annual license fee (in Dollars)									$ 10,000
THM [Member] | Biopharmaceutical Product [Member]
Commitments and Contingent Liabilities [Line Items]
Annual interest rate of revenues									3.50%	3.50%
THM [Member] | Diagnostic Products [Member]
Commitments and Contingent Liabilities [Line Items]
Annual interest rate of revenues									6.50%	6.50%
Percentage of sublicense consideration									12%	12%

Research and Development Expe_3

Research and Development Expenses (Details) - Schedule of Research and Development Expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Research and Development Expenses [Abstract]
Salaries, wages and related expenses	$ 2,323	$ 2,382	$ 1,721
Share-based payments (see also Note 11)	768	768	557
Service providers	13,943	13,170	9,549
Research and development expense, total	$ 17,034	$ 16,320	$ 11,827

Sales, General and Administra_3

Sales, General and Administrative Expenses (Details) - Schedule of Sales, General and Administrative Expenses - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Sales General and Administrative Expenses [Abstract]
Salaries, wages and related expenses	$ 1,769	$ 1,845	$ 1,762
Share-based payments (see also Note 11)	822	1,333	1,047
Legal fees in connection with ISA investigation and class action lawsuits (see also Note 13B)		135	12
Reimbursement of legal fees	(116)	(63)	(66)
Other professional fees	1,004	750	1,222
Board member remuneration and insurance	818	1,152	1,033
Board member share-based payments	284	311	478
Maintenance expenses	196	120	55
Travel and car expenses	130	144	133
Depreciation	199	201	231
Other	131	355	200
Sales, General and Administrative Expenses total	$ 5,237	$ 6,283	$ 6,107

Finance Expense (Income), Net_2

Finance Expense (Income), Net (Details)	12 Months Ended
	Dec. 31, 2023
Finance Expense (Income), Net [Abstract]
Warrants expire term	5 years 6 months

Finance Expense (Income), Net_3

Finance Expense (Income), Net (Details) - Schedule of Finance Expenses and Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Finance expenses
Fees and interest expense	$ 56	$ 67	$ 79
Loss from exchange rate differences, net	13		133
Issuance expenses (see note 10D)	2,126
Finance expenses, total	2,195	67	212
Finance income
Interest income from deposits	(474)	(532)	(320)
Income from exchange rate differences, net		(62)
Changes in fair value of finance instruments	(517)	(245)
Other	(1)	(71)
Finance income, total	$ (992)	$ (910)	$ (320)

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Taxes on Income [Abstract]
Tax rate applicable	23%	23%
Statutory tax rate.	23%
Tax benefit	$ 4.6
Effective tax rate	0%
Unrecognized research and development expenses	$ 96	$ 82	$ 59

Employee Benefits (Details)

Employee Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee Benefits [Line Items]
Bonuses expenses	$ 406	$ 446	$ 580
Employee benefits liability due grants	$ 141	$ 303

Employee Benefits (Details) - S

Employee Benefits (Details) - Schedule of Post-Employee Benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Post-Employee Benefits [Abstract]
Short-term benefits	$ 549	$ 463
Post-employment benefit liabilities	141	145
Post-employment benefit liabilities included in other payables		$ 158

Employee Benefits (Details) -_2

Employee Benefits (Details) - Schedule of Defined Contribution Plan in Respect of its Employees - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Defined Contribution Plan in Respect of its Employees [Abstract]
Amount recognized as expense in respect of defined contribution plan	$ 401	$ 390	$ 291

Financial Instruments (Details)

Financial Instruments (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended				12 Months Ended
	Jan. 31, 2024	Oct. 31, 2023	Oct. 31, 2021	Jun. 30, 2020	Dec. 31, 2023	Dec. 31, 2022
Financial Instruments [Line Items]
Cash and cash equivalents and short-term and long-terms deposits					$ 850	$ 16,652
Convertible note amount			$ 1,500
Convertible warrants (in Shares)			300,000
Termination exercise price (in Dollars per share)			$ 5
Fair value financial instruments					73	431
Warrants issued (in Shares)		4,347,827		555,555
Exercise price per share (in Dollars per share)				$ 9
Warrants exercise price per share (in Dollars per share)				$ 1.25
Financial instrument amount					$ 2,518
Top of range [Member]
Financial Instruments [Line Items]
Bear fixed interest, percentage					1%
Bottom of range [Member]
Financial Instruments [Line Items]
Bear fixed interest, percentage					5.40%
Credit risk [Member]
Financial Instruments [Line Items]
Cash and cash equivalents and short-term and long-terms deposits					$ 15,339	$ 31,682
Short term deposits guaranteed for leases and credit					139
Short term deposits					700
Convertible note amount					$ 625
Non-adjusting events after reporting period [Member]
Financial Instruments [Line Items]
Convertible note amount	$ 200

Financial Instruments (Detail_2

Financial Instruments (Details) - Schedule of Sensitivity Test to Possible Changes in Exchange Rate - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	$ (11)	$ (4)
Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(24)	(10)
Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	24	10
Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	11	4
Cash and cash equivalents and deposits [Member]
Financial Instrument [Line Items]
Income (loss) value	550	960
Cash and cash equivalents and deposits [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	11	19
Cash and cash equivalents and deposits [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	28	48
Cash and cash equivalents and deposits [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(28)	(48)
Cash and cash equivalents and deposits [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(11)	(19)
Other current assets [Member]
Financial Instrument [Line Items]
Income (loss) value	660	841
Other current assets [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	13	17
Other current assets [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	33	42
Other current assets [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(33)	(42)
Other current assets [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(13)	(17)
Accounts payable [Member]
Financial Instrument [Line Items]
Income (loss) value	(225)	(205)
Accounts payable [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(5)	(4)
Accounts payable [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(11)	(10)
Accounts payable [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	11	10
Accounts payable [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	5	4
Other payables [Member]
Financial Instrument [Line Items]
Income (loss) value	(1,340)	(1,668)
Other payables [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(27)	(33)
Other payables [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(67)	(83)
Other payables [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	67	83
Other payables [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	27	33
Post-employment benefit liabilities [Member]
Financial Instrument [Line Items]
Income (loss) value	(141)	(145)
Post-employment benefit liabilities [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(3)	(3)
Post-employment benefit liabilities [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(7)	(7)
Post-employment benefit liabilities [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	7	7
Post-employment benefit liabilities [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	3	3
EURO [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(7)	21
EURO [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(18)	53
EURO [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	18	(53)
EURO [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	7	(21)
EURO [Member] | Cash and cash equivalents and deposits [Member]
Financial Instrument [Line Items]
Income (loss) value	48	2,246
EURO [Member] | Cash and cash equivalents and deposits [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	1	45
EURO [Member] | Cash and cash equivalents and deposits [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	2	112
EURO [Member] | Cash and cash equivalents and deposits [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(2)	(112)
EURO [Member] | Cash and cash equivalents and deposits [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(1)	(45)
EURO [Member] | Accounts payable [Member]
Financial Instrument [Line Items]
Income (loss) value	(153)	(979)
EURO [Member] | Accounts payable [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(3)	(20)
EURO [Member] | Accounts payable [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(8)	(49)
EURO [Member] | Accounts payable [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	8	49
EURO [Member] | Accounts payable [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	3	20
EURO [Member] | Other payables [Member]
Financial Instrument [Line Items]
Income (loss) value	(232)	(207)
EURO [Member] | Other payables [Member] | Down 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(5)	(4)
EURO [Member] | Other payables [Member] | Down 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	(12)	(10)
EURO [Member] | Other payables [Member] | Up 5% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	12	10
EURO [Member] | Other payables [Member] | Up 2% [Member]
Financial Instrument [Line Items]
Income (loss) from change in exchange rate	$ 5	$ 4

Financial Instruments (Detail_3

Financial Instruments (Details) - Schedule of Financial Instruments Measured at Fair Value - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Financial asset and liabilities
Convertible debt instrument and warrant (see Note 19B (1))	$ 73	$ 431
Financial liability of warrants	2,518
Level 1 [Member]
Financial asset and liabilities
Convertible debt instrument and warrant (see Note 19B (1))
Financial liability of warrants
Level 2 [Member]
Financial asset and liabilities
Convertible debt instrument and warrant (see Note 19B (1))
Financial liability of warrants
Level 3 [Member]
Financial asset and liabilities
Convertible debt instrument and warrant (see Note 19B (1))	73	$ 431
Financial liability of warrants	$ 2,518

Financial Instruments (Detail_4

Financial Instruments (Details) - Schedule of Details Regarding Fair Value Measurement $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Convertible note [Member]
Financial Instruments (Details) - Schedule of Details Regarding Fair Value Measurement [Line Items]
Balance as of January 1, 2023	$ 431
Issuance
Proceed	(875)
Revaluation	517
Balance as of December 31, 2023	73
Warrants [Member]
Financial Instruments (Details) - Schedule of Details Regarding Fair Value Measurement [Line Items]
Balance as of January 1, 2023
Issuance	6,015
Proceed
Revaluation	(3,497)
Balance as of December 31, 2023	$ 2,518

Financial Instruments (Detail_5

Financial Instruments (Details) - Schedule of Fair Value Measurement	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Schedule of Fair Value Measurement [Line Items]
Expected volatility	70.89%
annual risk free interest	4.50%
dividend yield	0%
Convertible debt instrument [Member]
Schedule of Fair Value Measurement [Line Items]
DLOM	26.10%	37.60%
Warrants [Member]
Schedule of Fair Value Measurement [Line Items]
Expected term		1 year 8 months 19 days
Expected volatility		117.42%
annual risk free interest		4.47%
dividend yield		0%
Warrants [Member]
Schedule of Fair Value Measurement [Line Items]
Expected term	5 years 3 months 18 days
Expected volatility	89.94%
annual risk free interest	3.88%
dividend yield	0%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Events [Member]	Feb. 06, 2024 shares
Subsequent Events [Line Items]
Number of shares issued	816,827
Proceeds from exercise of warrants	816,827